US20080254142A1 - Compositions and methods for nutrition supplementation - Google Patents
Compositions and methods for nutrition supplementation Download PDFInfo
- Publication number
- US20080254142A1 US20080254142A1 US12/143,464 US14346408A US2008254142A1 US 20080254142 A1 US20080254142 A1 US 20080254142A1 US 14346408 A US14346408 A US 14346408A US 2008254142 A1 US2008254142 A1 US 2008254142A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- methods
- present
- compositions
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 238000000034 method Methods 0.000 title claims abstract description 75
- 235000016709 nutrition Nutrition 0.000 title abstract description 12
- 230000009469 supplementation Effects 0.000 title abstract description 7
- 230000035764 nutrition Effects 0.000 title description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 53
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 50
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 48
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 44
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 34
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 27
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 26
- 239000011575 calcium Substances 0.000 claims description 26
- 229910052791 calcium Inorganic materials 0.000 claims description 26
- 229910052742 iron Inorganic materials 0.000 claims description 25
- 235000001968 nicotinic acid Nutrition 0.000 claims description 25
- 229960003512 nicotinic acid Drugs 0.000 claims description 25
- 239000011664 nicotinic acid Substances 0.000 claims description 25
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 24
- 229930003427 Vitamin E Natural products 0.000 claims description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 24
- 235000019165 vitamin E Nutrition 0.000 claims description 24
- 239000011709 vitamin E Substances 0.000 claims description 24
- 229940046009 vitamin E Drugs 0.000 claims description 24
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 23
- 229930003268 Vitamin C Natural products 0.000 claims description 23
- 235000019152 folic acid Nutrition 0.000 claims description 23
- 239000011724 folic acid Substances 0.000 claims description 23
- 239000011777 magnesium Substances 0.000 claims description 23
- 229910052749 magnesium Inorganic materials 0.000 claims description 23
- 235000019154 vitamin C Nutrition 0.000 claims description 23
- 239000011718 vitamin C Substances 0.000 claims description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 21
- 229960000304 folic acid Drugs 0.000 claims description 21
- 229930003316 Vitamin D Natural products 0.000 claims description 20
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 20
- 235000019166 vitamin D Nutrition 0.000 claims description 20
- 239000011710 vitamin D Substances 0.000 claims description 20
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 20
- 229940046008 vitamin d Drugs 0.000 claims description 20
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 19
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 19
- 229910052802 copper Inorganic materials 0.000 claims description 19
- 239000010949 copper Substances 0.000 claims description 19
- 235000019155 vitamin A Nutrition 0.000 claims description 19
- 239000011719 vitamin A Substances 0.000 claims description 19
- 229940045997 vitamin a Drugs 0.000 claims description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 18
- 239000011701 zinc Substances 0.000 claims description 18
- 229910052725 zinc Inorganic materials 0.000 claims description 18
- 239000011691 vitamin B1 Substances 0.000 claims description 16
- 239000011715 vitamin B12 Substances 0.000 claims description 16
- 239000011726 vitamin B6 Substances 0.000 claims description 16
- 239000011716 vitamin B2 Substances 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 6
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 27
- 239000011707 mineral Substances 0.000 abstract description 27
- 229940088594 vitamin Drugs 0.000 abstract description 23
- 229930003231 vitamin Natural products 0.000 abstract description 23
- 235000013343 vitamin Nutrition 0.000 abstract description 23
- 239000011782 vitamin Substances 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 235000010755 mineral Nutrition 0.000 description 26
- 201000010099 disease Diseases 0.000 description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 20
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 230000035935 pregnancy Effects 0.000 description 14
- 150000003722 vitamin derivatives Chemical class 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 10
- 239000011677 pyridoxine Substances 0.000 description 10
- 235000008160 pyridoxine Nutrition 0.000 description 10
- 229940011671 vitamin b6 Drugs 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 9
- 239000007894 caplet Substances 0.000 description 9
- 239000005515 coenzyme Substances 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- 230000006651 lactation Effects 0.000 description 9
- 229960002477 riboflavin Drugs 0.000 description 9
- 235000019192 riboflavin Nutrition 0.000 description 9
- 239000002151 riboflavin Substances 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 6
- 208000002720 Malnutrition Diseases 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000009920 chelation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960002104 cyanocobalamin Drugs 0.000 description 5
- 239000011666 cyanocobalamin Substances 0.000 description 5
- 235000000639 cyanocobalamin Nutrition 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011570 nicotinamide Substances 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 235000003715 nutritional status Nutrition 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 201000011461 pre-eclampsia Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000019157 thiamine Nutrition 0.000 description 5
- 239000011721 thiamine Substances 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 4
- 239000005751 Copper oxide Substances 0.000 description 4
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 4
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 4
- 102000014701 Transketolase Human genes 0.000 description 4
- 108010043652 Transketolase Proteins 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910000431 copper oxide Inorganic materials 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 4
- 239000011773 ferrous fumarate Substances 0.000 description 4
- 229960000225 ferrous fumarate Drugs 0.000 description 4
- 235000002332 ferrous fumarate Nutrition 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000395 magnesium oxide Substances 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000018343 nutrient deficiency Nutrition 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- -1 serum-ferritin Proteins 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000011748 thiamine mononitrate Substances 0.000 description 4
- 229960004860 thiamine mononitrate Drugs 0.000 description 4
- 235000019191 thiamine mononitrate Nutrition 0.000 description 4
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 102100032241 Lactotransferrin Human genes 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 3
- 108700021020 Vitamin D-binding protein Proteins 0.000 description 3
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 102000036215 folic acid binding proteins Human genes 0.000 description 3
- 108091011001 folic acid binding proteins Proteins 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003979 granulating agent Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011585 methylcobalamin Substances 0.000 description 3
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 3
- 235000007672 methylcobalamin Nutrition 0.000 description 3
- 201000010193 neural tube defect Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000029752 retinol binding Human genes 0.000 description 3
- 108091000053 retinol binding Proteins 0.000 description 3
- 108010053455 riboflavin-binding protein Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010016880 Folate deficiency Diseases 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047631 Vitamin E deficiency Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- OAJLVMGLJZXSGX-NDSREFPTSA-L (2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12 Chemical compound [Co+3].O[C@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-NDSREFPTSA-L 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 201000009331 Choledocholithiasis Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 208000024815 Granulomatous liver disease Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000006529 extracellular process Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000017694 hepatic granuloma Diseases 0.000 description 1
- 231100000843 hepatic granuloma Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 1
- 239000011580 pyridoxamine 5'-phosphate Substances 0.000 description 1
- 235000008974 pyridoxamine 5'-phosphate Nutrition 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000012175 toxemia of pregnancy Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229940056345 tums Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/06—Chelate
Definitions
- the present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, subjects in physiologically stressful states.
- nutritional supplementation serves a vital role in protecting against poor nutrition and disease. More specifically, research has suggested that optimizing specific nutrients before, during, and after the physiological processes of pregnancy or lactation can have a profound, positive, and comprehensive impact upon the overall wellness of the developing and newborn child as well as the safety and health of the mother.
- the present inventions provide compositions and methods designed to supplement the nutritional needs of individuals within physiologically stressful states.
- the present invention provides compositions and methods of using these compositions for both prophylactic and therapeutic nutritional supplementation, specifically throughout physiologically stressful states.
- the present invention relates to novel compositions of vitamins and minerals that can be used to supplement the nutritional deficiencies observed in patients throughout physiologically stressful states such as, for example, pregnancy, lactation, and any disease state.
- compositions of the present invention may comprise less than about 160 mg calcium, more than about 20 mg iron, and copper in either chelated or non-chelated form.
- compositions of the present invention may comprise one or more of about 2430 IU to about 2970 IU of Vitamin A, about 360 IU to about 440 IU of Vitamin D, about 63 mg to about 77 mg of Vitamin C, about 27 IU to about 33 IU of Vitamin E, about 0.9 mg to about 1.1 mg of folic acid, about 1.44 mg to about 1.76 mg of Vitamin B 1 , about 1.62 mg to about 1.98 mg of Vitamin B 2 , about 2.25 mg to about 2.75 mg of Vitamin B 6 , about 10.8 mcg to about 13.2 mcg of Vitamin B 12 , about 16.2 mg to about 19.8 mg of niacin, about 90 mg to about 110 mg of calcium, about 58.5 mg to about 71.5 mg of iron, about 22.5 mg to about 27.5 mg of magnesium, about 22.5 mg to about 27.5 mg of zinc, and about 1.8 mg to about 2.2 mg of copper.
- compositions of the present invention may comprise one or more of 2700 IU of Vitamin A, 400 IU of Vitamin D, 70 mg of Vitamin C, 30 IU of Vitamin E, 1 mg of folic acid, 1.6 mg of Vitamin B 1 , 1.8 mg of Vitamin B 2 , 2.5 mg of Vitamin B 6 , 12 mcg of Vitamin B 12 , 18 mg of niacin, 100 mg of calcium, 65 mg of iron, 25 mg of magnesium, 25 mg of zinc, and 2 mg of copper.
- compositions of the present invention may be suitable for administration to subjects in physiologically stressful states.
- Such compositions may be suitable for treating nutritional deficiencies resulting from such physiologically stressful states, which may result from, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein.
- nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein.
- compositions of the present invention may comprise one or more compounds that serve as pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- compositions of the present invention may comprise one or more of Vitamin A in the form of beta carotene, Vitamin D in the form of cholecalciferol, Vitamin C in the form of ascorbic acid, Vitamin E in the form of dl-alpha-tocopheryl acetate, a B-complex vitamin in the form of folic acid, Vitamin B 1 in the form of thiamine mononitrate, Vitamin B 2 in the form of riboflavin, Vitamin B 6 in the form of pyridoxine hydrochloride, Vitamin B 12 in the form of cyanocobalamin, niacin in the form of niacinamide, calcium in the form of calcium carbonate, iron in the form of ferrous fumarate, magnesium in the form of magnesium oxide, zinc in the form of zinc oxide, and/or copper in the form of copper oxide.
- Vitamin A in the form of beta carotene Vitamin D in the form of cholecalciferol
- Vitamin C in the form of ascorbic acid
- Vitamin E in the form of
- the present invention also relates to methods for supplementing nutritional deficiencies in a patient or person throughout physiologically stressful states such as, for example, pregnancy, lactation, and any disease state.
- the methods of the present invention may comprise the step of administering to a patient a composition comprising less than about 160 mg calcium, more than about 20 mg iron, and copper in either chelated or non-chelated form.
- the methods of the present invention may utilize compositions comprising one or more of about 2430 IU to about 2970 IU of Vitamin A, about 360 IU to about 440 IU of Vitamin D, about 63 mg to about 77 mg of Vitamin C, about 27 IU to about 33 IU of Vitamin E, about 0.9 mg to about 1.1 mg of folic acid, about 1.44 mg to about 1.76 mg of Vitamin B 1 , about 1.62 mg to about 1.98 mg of Vitamin B 2 , about 2.25 mg to about 2.75 mg of Vitamin B 6 , about 10.8 mcg to about 13.2 mcg of Vitamin B 12 , about 16.2 mg to about 19.8 mg of niacin, about 90 mg to about 110 mg of calcium, about 58.5 mg to about 71.5 mg of iron, about 22.5 mg to about 27.5 mg of magnesium, about 22.5 mg to about 27.5 mg of zinc, and about 1.8 mg to about 2.2 mg of copper.
- the methods of the present invention may utilize compositions comprising one or more of 2700 IU of Vitamin A, 400 IU of Vitamin D, 70 mg of Vitamin C, 30 IU of Vitamin E, 1 mg of folic acid, 1.6 mg of Vitamin B 1 , 1.8 mg of Vitamin B 2 , 2.5 mg of Vitamin B 6 , 12 mcg of Vitamin B 12 , 18 mg of niacin, 100 mg of calcium, 65 mg of iron, 25 mg of magnesium, 25 mg of zinc, and 2 mg of copper.
- the methods of the present invention utilize the compositions of the present invention suitable for administration to subjects in physiologically stressful states.
- the methods of the present invention may be directed to the alleviation of nutritional deficiencies resulting from such physiologically stressful states, which may result from, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein.
- nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein,
- the methods of the present invention may utilize one or more compounds that serve as pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- the methods of the present invention may utilize compositions comprising one or more of Vitamin A in the form of beta carotene, Vitamin D in the form of cholecalciferol, Vitamin C in the form of ascorbic acid, Vitamin E in the form of dl-alpha-tocopheryl acetate, a B-complex vitamin in the form of folic acid, Vitamin B 1 in the form of thiamine mononitrate, Vitamin B 2 in the form of riboflavin, Vitamin B 6 in the form of pyridoxine hydrochloride, Vitamin B 12 in the form of cyanocobalamin, niacin in the form of niacinamide, calcium in the form of calcium carbonate, iron in the form of ferrous fumarate, magnesium in the form of magnesium oxide, zinc in the form of zinc oxide, and/or copper in the form of copper oxide.
- Vitamin A in the form of beta carotene Vitamin D in the form of cholecalciferol
- Vitamin C in the form of ascorbic acid
- Vitamin E
- disease state may comprise any state in which one or more organs or components of an organism malfunction.
- the term “disease state” may refer to any deterioration of any component of a body.
- the term “disease state” may refer to any deficiency of any compound necessary for the maintenance or function of any component of any organism.
- the term “disease state” may refer to any condition in which a body contains toxins, produced by microorganisms that infect the body or by body cells through faulty metabolism or absorbed from an external source. “Disease states” may be adverse states caused by any diet, any virus, or any bacteria.
- Disease states may comprise disorders associated with pregnant females such as, for example, osteomalacia and preeclampsia and disorders associated with a fetus such as, for example, neural tube defects and various fetal abnormalities.
- Disease states may comprise any pulmonary disorder such as, for example, bronchitis, bronchiectasis, atelectasis, pneumonia, diseases caused by inorganic dusts, diseases caused by organic dusts, any pulmonary fibrosis, and pleurisy.
- Disease states may comprise any hematological/oncological disorder such as, for example, anemia, hemophilia, leukemia, and lymphoma.
- a “disease state” may comprise any cancer such as, for example, breast cancer, lung cancer, prostate cancer, pancreatic cancer, liver cancer, stomach cancer, testicular cancer, ovarian cancer, skin cancer, cancer of the brain, cancer of the mouth, cancer of the throat, and cancer of the neck.
- “Disease states” may comprise any disorder of the immune system such as, for example, acquired immune deficiency syndrome (AIDS), AIDS-related complex, infection by any strain of any human immunodeficiency virus (HIV), and other viruses or pathogens such as bacteria.
- AIDS acquired immune deficiency syndrome
- HAV human immunodeficiency virus
- a “disease state” may comprise any cardiovascular disorder such as, for example, arterial hypertension, orthostatic hypotension, arteriosclerosis, coronary artery disease, cardiomyopathy, any arrhythmia, any valvular heart disease, endocarditis, pericardial disease, any cardiac tumor, any aneurysm, and any peripheral vascular disorder.
- “Disease states” may comprise any hepatic/biliary disorder such as, for example, jaundice, hepatic steatosis, fibrosis, cirrhosis, hepatitis, any hepatic granuloma, any liver tumor, cholelithiasis, cholecystitis, and choledocholithiasis.
- physiologically stressful state comprises any state of an organism in which the organism faces one or more physiological challenges.
- a “physiologically stressful state” may comprise pregnancy, lactation, or conditions in which an organism faces physiological challenges related to, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins.
- a “physiologically stressful state” may result from one or more disease states.
- subject comprises any and all organisms and includes the term “patient.” “Subject” may refer to a human or any other animal. “Subject” may also refer to a fetus.
- Proper nutrition is essential for maintaining health and preventing diseases. Adequate nutrition is especially critical during, for example, nutritionally volatile or physiologically stressful periods such as periods comprising, for example, pregnancy, lactation, or a disease state. Vitamin and mineral needs are almost universally increased throughout these periods.
- Increased needs during physiologically stressful states such as pregnancy or lactation may result from elevated metabolic demand, increased plasma volume, increased quantities of circulating red blood cells, decreased concentrations of nutrients, and decreased concentrations of nutrient-binding proteins such as, for example, serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein.
- serum-ferritin maltose-binding protein
- lactoferrin lactoferrin
- calmodulin tocopheryl binding protein
- riboflavin binding protein riboflavin binding protein
- retinol binding protein retinol binding protein
- transthyretin high density lipoprotein-apolipoprotein A1, folic acid binding protein
- 25-hydroxyvitamin D binding protein Lapido,
- compositions and methods of the present invention provide the means to optimize good health by utilizing vitamin and mineral nutritional supplementation.
- the compositions and methods of the present invention may be administered to or directed to a subject such as a human or any other organism.
- compositions and methods of the present invention may comprise or use Vitamin A.
- Vitamin A This vitamin functions in physiological processes resulting in cellular differentiation, cellular maturity, and cellular specificity.
- Vitamin A is an important component of a nutritional supplement for subjects in a physiologically stressful state, such as pregnant or lactating women. Zile et al., 131(3) J. Nutr. 705-08 (2001).
- the compounds and methods of the present invention may comprise a form of Vitamin A, specifically, for example, the pro-vitamin A carotenoid beta carotene. Beta carotene is converted to Vitamin A within the body as needed. Mayne, 10 FASEB J. 690-701 (1996).
- the novel compositions and methods of the present invention may comprise or use Vitamin A, specifically in amounts ranging from about 2430 IU to about 2970 IU and, in a specific embodiment, around 2700 IU.
- compositions and methods of the present invention may comprise or use Vitamin D.
- Vitamin D is a fat-soluble “hormone like” substance important for the maintenance of healthy bones. This vitamin increases the absorption of calcium and phosphorus from the gastrointestinal tract, and improves mineral resorption into bone tissue. Vitamin D can be converted to its active form from exposure of the skin to sunlight. This fact is among the reasons why Vitamin D deficiency is common in the elderly, notably the institutionalized, who spend little or no time out of doors. Deficiencies lead to increased bone turnover and loss, and when severe, osteomalacia, or softening of the bones. Supplementation with Vitamin D has been shown to moderately reduce bone loss, increase serum 25-hydroxyvitamin D, and decrease serum parathyroid hormone levels.
- the Vitamin D of the compositions and methods of the present invention may comprise Vitamin D 3 (cholecalciferol).
- Vitamin D 3 is produced when its precursor is exposed to ultraviolet irradiation (e.g., sunlight) and then hydroxylated in the liver to form 25-hydroxyvitamin D 3 , a form of Vitamin D in circulation.
- This form of the vitamin may be hydroxylated again in the kidney, yielding 1,25-hydroxyvitamin D 3 , a potent form of Vitamin D.
- Vitamin D 3 plays a role in the maintenance of calcium and phosphorus homeostasis, but it is also active in cell differentiation and immune function.
- the novel compositions and methods of the present invention may comprise or use Vitamin D, specifically in amounts ranging from about 360 IU to about 440 IU and, in a specific embodiment, around 400 IU.
- compositions and methods of the present invention may comprise or use Vitamin C (also known as ascorbic acid).
- Vitamin C also known as ascorbic acid.
- the major biochemical role of the water-soluble Vitamin C is as a co-substrate in metal catalyzed hydroxylations.
- Vitamin C has antioxidant properties in interacting directly with superoxide hydroxyl radicals and singlet oxygen.
- Vitamin C also provides antioxidant protection for folate and Vitamin E, keeping Vitamin E in its most potent form.
- Lipid peroxidation has been associated with over 200 disease processes. Rock et al., 96(7) J. A MER. D IET. A SSOC. 693-702 (1996). Specifically, lipid peroxidation may be implicated, for example, in the pathophysiology of preeclampsia, a toxemia of pregnancy. Vitamin C may afford protective effects against preeclampsia by participating in the scavenging of free radicals. Indeed, significantly lower levels of Vitamin C have been observed in preeclamptic women than in controls. Woods et al., 185(1) AM. J. O BSTET. G YNECOL. 5-10 (2001); Kharb, 1 E URO. J. O BSTET. G YNECOL. R EPROD. B IOL. 37-39 (2000); Milczarek et al., 210 M OL. C ELL. B IOCHEM. 65-73 (2000).
- Vitamin C also enhances the absorption of iron. N ATIONAL R ESEARCH C OUNCIL, R ECOMMENDED D IETARY A LLOWANCES 115 (10th ed. 1989) (hereinafter “RDA”).
- RDA R ECOMMENDED D IETARY A LLOWANCES 115 (10th ed. 1989)
- Vitamin C is required for collagen synthesis, epinephrine synthesis, and bile acid formation.
- Vitamin C has been implicated in inhibiting atherosclerosis by being present in extracellular fluid of the arterial wall and potentiating nitric oxide activity, thus normalizing vascular function.
- the novel compositions and methods of the present invention may comprise or use Vitamin C, specifically in amounts ranging from about 63 mg to about 77 mg and, in a specific embodiment, around 70 mg.
- compositions and methods of the present invention may comprise or use Vitamin E.
- Vitamin E is a fat-soluble vitamin antioxidant found in biological membranes where it protects the phospholipid membrane from oxidative stress.
- One form of Vitamin E dl-alpha-tocopheryl acetate (BASF Corporation, Mount Olive, N.J.), is used to fortify foods and pharmaceuticals and may be used within the context of the present invention.
- Vitamin E inhibits the oxidation of unsaturated fatty acids by trapping peroxyl free radicals. It is also an antiatherogenic agent, and studies have demonstrated a reduced risk of coronary heart disease with increased intake of Vitamin E. Stampfer et al., 328 N EW E NG. J. M ED. 1444-49 (1993).
- Vitamin E may afford protective effects against preeclampsia by participating in the scavenging of free radicals. Indeed, significantly lower levels of Vitamin E have been observed in preeclamptic women than in controls. Woods et al., 185(1) A M. J. O BSTET. G YNECOL. 5-10 (2001); Kharb, 1 E URO. J. O BSTET. G YNECOL. R EPROD. B IOL. 37-39 (2000); Milczarek et al., 210 M OL. C ELL. B IOCHEM. 65-73 (2000).
- the novel compositions and methods of the present invention may comprise or use Vitamin E, specifically in amounts ranging from about 27 IU to about 33 IU and, in a specific embodiment, around 30 IU.
- compositions and methods of the present invention may comprise or use B-complex vitamins.
- This class of vitamins comprises the water-soluble nutrients not generally stored in the body.
- the B-complex vitamins of the present compositions and methods may comprise one or more of thiamine (B 1 ), riboflavin (B 2 ), niacin (B 3 ), folic acid, pyridoxine (B 6 ) and cyanocobalamin (B 12 ).
- B-complex vitamins play roles in a variety of biological processes critical to the health of pregnant women, lactating women, and fetuses such as, for example, the metabolism of homocysteine.
- compositions and methods of the present invention may comprise or use folic acid.
- the B-complex vitamin folic acid has demonstrated the ability to prevent neural tube defects such as spina bifida caused by disturbed homocysteine metabolism. Vanderput et al., E XP. B IOL. M ED. 243-70 (2001); DeFalco et al., 27 C LIN. E XP. O BSTET. G YNECOL. 188-90 (2000); Eskes, 27 C LIN. E XP. O BSTET. G 157-67 (2000); locksmith & Duff, 91 O BSTET. G YNECOL. 1027-34 (1998).
- folic acid is important for the formation of red and white blood cells within bone marrow and plays a role in heme formation. RDA at 150.
- the novel compositions and methods of the present invention may comprise or use folic acid, specifically in amounts ranging from about 0.9 mg to about 1.1 mg and, in a specific embodiment, around 1.0 mg.
- compositions and methods of the present invention may comprise or use Vitamin B 1 .
- Vitamin B 1 This vitamin plays a role in carbohydrate metabolism and neural function. It is a coenzyme for the oxidative decarboxylation of alpha-ketoacids (e.g., alpha-ketoglutarate and pyruvate) and for transketolase which is a component of the pentose phosphate pathway. Folate deficiency and malnutrition inhibit the activity of thiamine. RDA at 123. Vitamin B 1 is available in forms known to those of skill in the art, including the form of thiamine mononitrate (BASF Corporation, Mount Olive, N.J.).
- the novel compositions and methods of the present invention may comprise or use Vitamin B 1 , specifically in amounts ranging from about 1.44 mg to about 1.76 mg and, in a specific embodiment, around 1.6 mg.
- compositions and methods of the present invention may comprise or use Vitamin B 2 (riboflavin).
- Riboflavin is a component of two flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These flavoenzymes are involved in a number of oxidation-reduction reactions including the conversion of pyridoxine and niacin. RDA at 132. Flavoenzymes also play a role in a number of metabolic pathways such as amino acid deamination, purine degradation, and fatty acid oxidation and thus help to maintain carbohydrate, amino acid, and lipid metabolism.
- the novel compositions and methods of the present invention may comprise or use Vitamin B 2 , specifically in amounts ranging from about 1.62 mg to about 1.98 mg and, in a specific embodiment, around 1.8 mg.
- compositions and methods of the present invention may comprise or use Vitamin B 6 (pyridoxine).
- pyridoxine may reduce the levels of homocysteine. Bostom et al., 49 K IDNEY I NT. 147-52 (1996).
- the active forms of pyridoxine, pyridoxal-5′-phosphate (PLP) and pyridoxamine-5′-phosphate are coenzymes for numerous enzymes and as such, are important for gluconeogenesis, niacin formation, and erythrocyte metabolism. RDA at 142-43.
- Pyridoxine is a coenzyme for both cystathionine synthase and cystathionase, enzymes that catalyze the formation of cysteine from methionine.
- Homocysteine is an intermediate in this process and elevated levels of plasma homocysteine are recognized as a risk factor for both vascular disease (Robinson et al., 94 C IRCULATION 2743-48 (1996)) and neural tube defects (Locksmith & Duff, 91 O BSTET. G YNECOL. 1027-34 (1998)).
- Vitamin B 6 is available in forms known to those of skill in the art, including the form of pyridoxine hydrochloride (BASF Corporation, Mount Olive, N.J.).
- the novel compositions and methods of the present invention may comprise or use Vitamin B 6 , specifically in amounts ranging from about 2.25 mg to about 2.75 mg and, in a specific embodiment, around 2.5 mg.
- compositions and methods of the present invention may comprise or use Vitamin B 12 .
- Cobalamin (a form of Vitamin B 12 ) can be converted to the active coenzymes, methylcobalamin and 5′-deoxyadenosylcobalamin. These coenzymes are necessary for folic acid metabolism, conversion of coenzyme A, and myelin synthesis.
- methylcobalamin catalyzes the demethylation of a folate cofactor which is involved in DNA synthesis. A lack of demethylation may result in folic acid deficiency. RDA at 159-60.
- Deoxyadenosylcobalamin is the coenzyme for the conversion of methylmalonyl-CoA to succinyl-CoA, which plays a role in the citric acid cycle.
- cobalamin along with pyridoxine and folic acid in implicated in the proper metabolism of homocysteine.
- Cobalamin is available as cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin, and hydroxycyanocobalamin.
- the novel compositions and methods of the present invention may comprise or use Vitamin B 12 , specifically in amounts ranging from about 10.8 mcg to about 13.2 mcg and, in a specific embodiment, around 12 mcg.
- compositions and methods of the present invention may comprise or use niacin.
- Niacin also called Vitamin B 3
- nicotinic acid also called niacin
- niacinamide also called nicotinamide
- Niacin is particularly important for maintaining healthy levels and types of fatty acids.
- Niacin is also required for the synthesis of pyroxidine, riboflavin, and folic acid. RDA at 137.
- Administration of niacin may also effect a reduction in total cholesterol (LDL) and very low density lipoprotein (VLDL) levels and an increase in high density lipoprotein (HDL) cholesterol levels.
- LDL total cholesterol
- VLDL very low density lipoprotein
- HDL high density lipoprotein
- Nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP) are active coenzymes of niacin. These coenzymes are involved in numerous enzymatic reactions such as glycolysis, fatty acid metabolism, and steroid synthesis. Henkin et al., 91 A M. J. M ED. 239-46 (1991).
- the novel compositions and methods of the present invention may comprise or use niacin, specifically in amounts ranging from about 16.2 mg to about 19.8 mg and, in a specific embodiment, around 18 mg.
- Minerals are inorganic, or non-carbon-containing, elements that are critical for healthy physiological processes. Minerals are contemplated in the compositions and methods of the present invention. Such minerals may be in either chelated or non-chelated form. For example, minerals act as cofactors for hundreds of enzymes associated, for example, with food digestion, nucleic acid production, and protein synthesis. Minerals may also act as, for example, cofactors for antioxidant enzymes.
- the minerals of the compositions and methods of the present invention may comprise one or more of calcium, iron, magnesium, zinc, and copper.
- compositions and methods of the present invention may comprise or use calcium in either chelated or non-chelated form.
- Chelation of calcium may affect its bioavailability.
- C HELATED M INERALS available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002).
- This mineral is required for proper functioning of numerous intracellular and extracellular processes including, for example, muscle contraction, nerve conduction, blood coagulation, and of particular interest in the context of pregnancy and lactation, hormone release.
- the calcium ion plays a unique role in intracellular signaling and is involved in the regulation of many enzymes.
- T HE M ERCK M ANUAL OF D IAGNOSIS AND T HERAPY 139 Mark H. Beers, M. D.
- novel compositions and methods of the present invention may comprise or use calcium, specifically in amounts ranging from about 90 mg to about 110 mg and, in a specific embodiment, around 100 mg. Further, the novel compositions and methods of the present invention may comprise or use calcium in amounts less than about 160 mg. In addition, the novel compositions and methods of the present invention may comprise or use calcium in amounts ranging from about 0.001 mg to about 160 mg.
- novel compositions and methods of the present invention may comprise or use calcium in amounts of 0 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg
- compositions and methods of the present invention may comprise or use iron in either chelated or non-chelated form.
- Chelation of iron may affect its bioavailability.
- C HELATED M INERALS available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002).
- a primary function of iron is to carry oxygen to bodily tissues via the hemoglobin part of red blood cells. Supplemental intake of iron is critical to preventing anemia, a disorder associated with a variety of physiological states including, for example, pregnancy. Bothwell, 72(Supp.) A M. J. C LIN. N UTR. 257S-64S (2000). Severe anemia may have adverse effects upon a mother and a fetus.
- novel compositions and methods of the present invention may comprise or use iron, specifically in amounts ranging from about 58.5 mg to about 71.5 mg and, in a specific embodiment, around 65 mg. In addition, the novel compositions and methods of the present invention may comprise or use iron in amounts more than about 20 mg.
- novel compositions and methods of the present invention may comprise or use iron in amounts of 0 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg
- compositions and methods of the present invention may comprise or use magnesium in either chelated or non-chelated form.
- Chelation of magnesium may affect its bioavailability.
- C HELATED M INERALS available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002).
- Magnesium is important for over 300 different enzyme reactions. A primary function of magnesium is to bind to phosphate groups in adenosine triphosphate (ATP), thereby forming a complex that assists in the transfer of ATP phosphate.
- ATP adenosine triphosphate
- Magnesium also functions within cells as an allosteric activator of enzyme activity and for membrane stabilization. Magnesium also plays roles in nucleic acid synthesis, transcription of DNA and RNA, amino acid activation, and protein synthesis. J AMES L. L. G ROFF ET AL., A DVANCED N UTRITION AND H UMAN M ETABOLISM 341 (2d ed. 1996).
- Magnesium is found primarily in both bone and muscle. Magnesium is related to the reactions of over 300 enzymes, including enzymes associated with biosynthetic pathways, glycolysis, protein synthesis, transketolase reactions, and membrane transport. Magnesium is also involved in the formation of cAMP, a cytosolic second messenger that plays a role in cell signaling mechanisms. In addition, magnesium functions both synergistically and antagonistically with calcium in neuromuscular transmission. RDA at 188. Specifically, magnesium is critical for the maintenance of electrochemical potentials of nerve and muscle membranes and the neuromuscular junction transmissions, particularly important in the heart. Not surprisingly, magnesium deficiency is tied to cardiovascular disease and hypertension. Agus et al., 17 C RIT. C ARE C LINICS 175-87 (2001). Indeed, oral magnesium therapy improves endothelial function in patients with coronary disease. Shechter et al., 102 C IRCULATION 2353-58 (2000).
- Magnesium is available in a variety of salts.
- One form of magnesium known in the art is magnesium oxide (Mallinckrodt Baker, Inc., Phillipsburg, N.J.).
- the novel compositions and methods of the present invention may comprise or use magnesium, specifically in amounts ranging from about 22.5 mg to about 27.5 mg and, in a specific embodiment, around 25 mg.
- compositions and methods of the present invention may comprise or use zinc in either chelated or non-chelated form.
- Chelation of zinc may affect its bioavailability.
- C HELATED M INERALS available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002).
- Zinc plays a role in numerous metabolic activities such as nucleic acid production, protein synthesis, and development of the immune system.
- Zinc stabilizes RNA and DNA structures, forms zinc fingers in nuclear receptors, and is a component of chromatin proteins involved in transcription and replication. Deficiencies of zinc during pregnancy have been shown to contribute to severe fetal abnormalities. Srinivas et al., 68(6) I NDIAN J. P EDIATR. 519-22 (2001); Yang et al., 13(4) B IOMED. E NVIRON. S CI. 280-86 (2000); King, 71(Supp.) A M. J. C LIN. N UTR. 1334S-43S (2000).
- Zinc is available in many forms, such as zinc oxide (Reade Advanced Materials, Buffalo, R.I.) and zinc sulfate (United States Biological, Swampscott, Mass.).
- the novel compositions and methods of the present invention may comprise or use zinc, specifically in amounts ranging from about 22.5 mg to about 27.5 mg and, in a specific embodiment, around 25 mg.
- compositions and methods of the present invention may comprise or use copper in either chelated or non-chelated form.
- Chelation of copper may affect its bioavailability.
- C HELATED M INERALS available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002).
- Copper is an important component of the process of gene expression. Deficiencies of copper may lead to anemia, neutropenia, and bone abnormalities in pregnant and lactating women.
- a fetus must accumulate copper at a rate of 50 ⁇ g ⁇ kg ⁇ 1 ⁇ d ⁇ 1 over the latter half of pregnancy; any deficiency in accumulation may lead to low birth weight and protein-energy malnutrition.
- novel compositions and methods of the present invention may comprise or use copper, specifically in amounts ranging from about 1.8 mg to about 2.2 mg and, in a specific embodiment, around 2.0 mg.
- novel compositions and methods of the present invention may comprise or use copper, specifically in amounts of 0 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2.0 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg, or 3.0 mg.
- compositions and methods of the present invention may comprise or use a combination of vitamins and minerals, in either chelated or non-chelated form, that work together with various metabolic systems and physiological responses of the human body.
- the active ingredients are available from numerous commercial sources, and in several active forms or salts thereof, known to those of ordinary skill in the art. Hence, the compositions and methods of the present invention are not limited to comprising or using any particular form of the vitamin or mineral ingredient described herein.
- the ingredients of the present invention may be combined into a composition which may be in the form of a solid powder, caplets, tablets, lozenges, pills, capsules, or a liquid, and which may be administered alone or in suitable combination with other components.
- the composition of the present invention may be administered in one or more caplets or lozenges as practical for ease of administration.
- Each of the vitamins and minerals is commercially available, and can be blended to form a single composition or can form multiple compositions, which may be co-administered.
- each of the active ingredients may be combined in intimate admixture with a suitable carrier according to conventional compounding techniques.
- the carrier may take a wide variety of forms depending upon the form of the preparation desired for administration, e.g., oral, sublingual, nasal, via topical patch, or parenteral.
- the composition may consist of one to three caplets or lozenges, the composition of each preferably being identical to each other caplet or lozenge.
- any usual media may be utilized.
- liquid preparations e.g., suspensions, elixirs, and solutions
- media containing, for example water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used.
- Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used to prepare oral solids (e.g., powders, caplets, pills, tablets, capsules, and lozenges). Controlled release forms may also be used. Because of their ease in administration, caplets, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid carriers are employed.
- tablets may be sugar coated or enteric coated by standard techniques. All of these pharmaceutical carriers and formulations are well known to those of ordinary skill in the art. See generally, e.g., W ADE & W ALLER, H ANDBOOK OF P HARMACEUTICAL E XCIPIENTS (2nd ed. 1994).
- composition of the following formulation was prepared in caplet form, including the appropriate excipients, by standard methods known to those of ordinary skill in the art:
- Vitamin A (beta carotene) 2700 IU Vitamin D (cholecalciferol) 400 IU Vitamin C (ascorbic acid) 70 mg Vitamin E (dl-alpha-tocopheryl acetate) 30 IU folic acid 1.0 mg Vitamin B 1 (thiamine mononitrate) 1.6 mg Vitamin B 2 (riboflavin) 1.8 mg Vitamin B 6 (pyridoxine hydrochloride) 2.5 mg Vitamin B 12 (cyanocobalamin) 12 mcg niacin (niacinamide) 18 mg calcium (calcium carbonate) 100 mg iron (ferrous fumarate) 65 mg magnesium (magnesium oxide) 25 mg zinc (zinc oxide) 25 mg copper (copper oxide) 2.0 mg
- a study is undertaken to evaluate the effectiveness of the composition of the present invention in the treatment of patients.
- the objective of the study is to determine whether oral intake of the composition results in an improvement of the nutritional status of a patient in a physiologically stressful state.
- a double-blind, placebo controlled study is conducted over a six-month period.
- a total of 120 subjects 60 pregnant women entering the second trimester of pregnancy and 60 lactating women), aged 20-35 years, are chosen for the study.
- An initial assessment of the nutritional status of each woman is conducted utilizing methods such as the peroxide hemolysis test to assess Vitamin E deficiency, measurement of erythrocyte transketolase activity to determine thiamine levels, determination of erythrocyte glutathione reductase activity to assess riboflavin status, and high performance liquid chromatography to directly measure pyridoxine levels.
- the 120 subjects are separated into four separate groups of 30 women.
- each subject is administered 2 caplets, daily, of the composition as described in Example 1.
- each subject is administered 2 placebo caplets, daily. No other nutritional supplements are taken by the subjects during the assessment period.
- An assessment of the nutritional status of each woman is conducted utilizing methods such as the peroxide hemolysis test to assess Vitamin E deficiency, measurement of erythrocyte transketolase activity to determine thiamine levels, determination of erythrocyte glutathione reductase activity to assess riboflavin status, and high performance liquid chromatography to directly measure pyridoxine levels at one month intervals for a six month period.
- the data is evaluated using multiple linear regression analysis and a standard t-test.
- the baseline value of the outcome variable is included in the model as a covariant. Treatment by covariant interaction effects is tested by the method outlined by Weigel & Narvaez, 12 C ONTROLLED C LINICAL T RIALS 378-94 (1991).
- the regression model assumptions of normality and homogeneity of variance of residuals are evaluated by inspection of the plots of residuals versus predicted values. Detection of the temporal onset of effects is done sequentially by testing for the presence of significant treatment effects at 1, 2, 3, 4, 5, and 6 months, proceeding to the earlier time in sequence only when significant effects have been identified at each later time period. Changes from the baseline within each group are evaluated using paired t-tests. In addition, analysis of variance is performed on all baseline measurements and measurable subject characteristics to assess homogeneity between groups. All statistical procedures are conducted using the Statistical Analysis System (SAS Institute Inc., Cary, N.C.). An alpha level of 0.05 is used in all statistical tests.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.
Description
- The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, subjects in physiologically stressful states.
- Nutrition plays a critical role in maintaining good health. Proper nutrition prevents dietary deficiencies, and also protects against the development of disease. Proper nutrition plays an increasingly important role as the body faces physiological stress. For example, pregnancy and lactation are among the most nutritionally volatile and physiologically stressful periods and processes in the lifetimes of women. Specifically, vitamin and mineral needs are almost universally increased during these natural processes. These increased needs are almost always due to elevated metabolic demand, increased plasma volume, increased levels of blood cells, decreased concentrations of nutrients, and decreased concentrations of nutrient-binding proteins.
- Thus, nutritional supplementation serves a vital role in protecting against poor nutrition and disease. More specifically, research has suggested that optimizing specific nutrients before, during, and after the physiological processes of pregnancy or lactation can have a profound, positive, and comprehensive impact upon the overall wellness of the developing and newborn child as well as the safety and health of the mother. The present inventions provide compositions and methods designed to supplement the nutritional needs of individuals within physiologically stressful states.
- The present invention provides compositions and methods of using these compositions for both prophylactic and therapeutic nutritional supplementation, specifically throughout physiologically stressful states.
- Specifically, for example, the present invention relates to novel compositions of vitamins and minerals that can be used to supplement the nutritional deficiencies observed in patients throughout physiologically stressful states such as, for example, pregnancy, lactation, and any disease state.
- In one embodiment, the compositions of the present invention may comprise less than about 160 mg calcium, more than about 20 mg iron, and copper in either chelated or non-chelated form.
- In another embodiment, the compositions of the present invention may comprise one or more of about 2430 IU to about 2970 IU of Vitamin A, about 360 IU to about 440 IU of Vitamin D, about 63 mg to about 77 mg of Vitamin C, about 27 IU to about 33 IU of Vitamin E, about 0.9 mg to about 1.1 mg of folic acid, about 1.44 mg to about 1.76 mg of Vitamin B1, about 1.62 mg to about 1.98 mg of Vitamin B2, about 2.25 mg to about 2.75 mg of Vitamin B6, about 10.8 mcg to about 13.2 mcg of Vitamin B12, about 16.2 mg to about 19.8 mg of niacin, about 90 mg to about 110 mg of calcium, about 58.5 mg to about 71.5 mg of iron, about 22.5 mg to about 27.5 mg of magnesium, about 22.5 mg to about 27.5 mg of zinc, and about 1.8 mg to about 2.2 mg of copper.
- In yet another embodiment, the compositions of the present invention may comprise one or more of 2700 IU of Vitamin A, 400 IU of Vitamin D, 70 mg of Vitamin C, 30 IU of Vitamin E, 1 mg of folic acid, 1.6 mg of Vitamin B1, 1.8 mg of Vitamin B2, 2.5 mg of Vitamin B6, 12 mcg of Vitamin B12, 18 mg of niacin, 100 mg of calcium, 65 mg of iron, 25 mg of magnesium, 25 mg of zinc, and 2 mg of copper.
- In an embodiment, the compositions of the present invention may be suitable for administration to subjects in physiologically stressful states. Such compositions may be suitable for treating nutritional deficiencies resulting from such physiologically stressful states, which may result from, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein. The compositions of the present invention may comprise one or more compounds that serve as pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- In one embodiment, the compositions of the present invention may comprise one or more of Vitamin A in the form of beta carotene, Vitamin D in the form of cholecalciferol, Vitamin C in the form of ascorbic acid, Vitamin E in the form of dl-alpha-tocopheryl acetate, a B-complex vitamin in the form of folic acid, Vitamin B1 in the form of thiamine mononitrate, Vitamin B2 in the form of riboflavin, Vitamin B6 in the form of pyridoxine hydrochloride, Vitamin B12 in the form of cyanocobalamin, niacin in the form of niacinamide, calcium in the form of calcium carbonate, iron in the form of ferrous fumarate, magnesium in the form of magnesium oxide, zinc in the form of zinc oxide, and/or copper in the form of copper oxide.
- The present invention also relates to methods for supplementing nutritional deficiencies in a patient or person throughout physiologically stressful states such as, for example, pregnancy, lactation, and any disease state.
- In an embodiment, the methods of the present invention may comprise the step of administering to a patient a composition comprising less than about 160 mg calcium, more than about 20 mg iron, and copper in either chelated or non-chelated form.
- In another embodiment, the methods of the present invention may utilize compositions comprising one or more of about 2430 IU to about 2970 IU of Vitamin A, about 360 IU to about 440 IU of Vitamin D, about 63 mg to about 77 mg of Vitamin C, about 27 IU to about 33 IU of Vitamin E, about 0.9 mg to about 1.1 mg of folic acid, about 1.44 mg to about 1.76 mg of Vitamin B1, about 1.62 mg to about 1.98 mg of Vitamin B2, about 2.25 mg to about 2.75 mg of Vitamin B6, about 10.8 mcg to about 13.2 mcg of Vitamin B12, about 16.2 mg to about 19.8 mg of niacin, about 90 mg to about 110 mg of calcium, about 58.5 mg to about 71.5 mg of iron, about 22.5 mg to about 27.5 mg of magnesium, about 22.5 mg to about 27.5 mg of zinc, and about 1.8 mg to about 2.2 mg of copper.
- In yet another embodiment, the methods of the present invention may utilize compositions comprising one or more of 2700 IU of Vitamin A, 400 IU of Vitamin D, 70 mg of Vitamin C, 30 IU of Vitamin E, 1 mg of folic acid, 1.6 mg of Vitamin B1, 1.8 mg of Vitamin B2, 2.5 mg of Vitamin B6, 12 mcg of Vitamin B12, 18 mg of niacin, 100 mg of calcium, 65 mg of iron, 25 mg of magnesium, 25 mg of zinc, and 2 mg of copper.
- In an embodiment, the methods of the present invention utilize the compositions of the present invention suitable for administration to subjects in physiologically stressful states. The methods of the present invention may be directed to the alleviation of nutritional deficiencies resulting from such physiologically stressful states, which may result from, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins such as serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein. The methods of the present invention may utilize one or more compounds that serve as pharmaceutical carriers such as water, oil, alcohol, any flavoring agent, any preservative, any coloring agent, starch, any sugar, any diluent, any granulating agent, any lubricant, any binder, and any disintegrating agent.
- In one embodiment, the methods of the present invention may utilize compositions comprising one or more of Vitamin A in the form of beta carotene, Vitamin D in the form of cholecalciferol, Vitamin C in the form of ascorbic acid, Vitamin E in the form of dl-alpha-tocopheryl acetate, a B-complex vitamin in the form of folic acid, Vitamin B1 in the form of thiamine mononitrate, Vitamin B2 in the form of riboflavin, Vitamin B6 in the form of pyridoxine hydrochloride, Vitamin B12 in the form of cyanocobalamin, niacin in the form of niacinamide, calcium in the form of calcium carbonate, iron in the form of ferrous fumarate, magnesium in the form of magnesium oxide, zinc in the form of zinc oxide, and/or copper in the form of copper oxide.
- Other objectives, features and advantages of the present invention will become apparent from the following detailed description. The detailed description and the specific examples, although indicating specific embodiments of the invention, are provided by way of illustration only. Accordingly, the present invention also includes those various changes and modifications within the spirit and scope of the invention that may become apparent to those skilled in the art from this detailed description.
- It is understood that the present invention is not limited to the particular methodologies, protocols, solvents, and reagents, etc., described herein, as these may vary. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a vitamin” is a reference to one or more vitamins and includes equivalents thereof known to those skilled in the art and so forth.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Preferred methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All references cited herein are incorporated by reference herein in their entirety.
- The term “disease state” as used herein, may comprise any state in which one or more organs or components of an organism malfunction. The term “disease state” may refer to any deterioration of any component of a body. The term “disease state” may refer to any deficiency of any compound necessary for the maintenance or function of any component of any organism. The term “disease state” may refer to any condition in which a body contains toxins, produced by microorganisms that infect the body or by body cells through faulty metabolism or absorbed from an external source. “Disease states” may be adverse states caused by any diet, any virus, or any bacteria. “Disease states” may comprise disorders associated with pregnant females such as, for example, osteomalacia and preeclampsia and disorders associated with a fetus such as, for example, neural tube defects and various fetal abnormalities. “Disease states” may comprise any pulmonary disorder such as, for example, bronchitis, bronchiectasis, atelectasis, pneumonia, diseases caused by inorganic dusts, diseases caused by organic dusts, any pulmonary fibrosis, and pleurisy. “Disease states” may comprise any hematological/oncological disorder such as, for example, anemia, hemophilia, leukemia, and lymphoma. A “disease state” may comprise any cancer such as, for example, breast cancer, lung cancer, prostate cancer, pancreatic cancer, liver cancer, stomach cancer, testicular cancer, ovarian cancer, skin cancer, cancer of the brain, cancer of the mouth, cancer of the throat, and cancer of the neck. “Disease states” may comprise any disorder of the immune system such as, for example, acquired immune deficiency syndrome (AIDS), AIDS-related complex, infection by any strain of any human immunodeficiency virus (HIV), and other viruses or pathogens such as bacteria. A “disease state” may comprise any cardiovascular disorder such as, for example, arterial hypertension, orthostatic hypotension, arteriosclerosis, coronary artery disease, cardiomyopathy, any arrhythmia, any valvular heart disease, endocarditis, pericardial disease, any cardiac tumor, any aneurysm, and any peripheral vascular disorder. “Disease states” may comprise any hepatic/biliary disorder such as, for example, jaundice, hepatic steatosis, fibrosis, cirrhosis, hepatitis, any hepatic granuloma, any liver tumor, cholelithiasis, cholecystitis, and choledocholithiasis.
- The term “physiologically stressful state,” as used herein, comprises any state of an organism in which the organism faces one or more physiological challenges. A “physiologically stressful state” may comprise pregnancy, lactation, or conditions in which an organism faces physiological challenges related to, for example, elevated metabolic demand, increased plasma volume, or decreased concentrations of nutrient-binding proteins. A “physiologically stressful state” may result from one or more disease states.
- The term “subject,” as used herein, comprises any and all organisms and includes the term “patient.” “Subject” may refer to a human or any other animal. “Subject” may also refer to a fetus.
- Proper nutrition is essential for maintaining health and preventing diseases. Adequate nutrition is especially critical during, for example, nutritionally volatile or physiologically stressful periods such as periods comprising, for example, pregnancy, lactation, or a disease state. Vitamin and mineral needs are almost universally increased throughout these periods. Increased needs during physiologically stressful states such as pregnancy or lactation, for example, may result from elevated metabolic demand, increased plasma volume, increased quantities of circulating red blood cells, decreased concentrations of nutrients, and decreased concentrations of nutrient-binding proteins such as, for example, serum-ferritin, maltose-binding protein, lactoferrin, calmodulin, tocopheryl binding protein, riboflavin binding protein, retinol binding protein, transthyretin, high density lipoprotein-apolipoprotein A1, folic acid binding protein, and 25-hydroxyvitamin D binding protein. Lapido, 72(Supp.) A
MER. J. CLIN. NUTR. 280S-90S (2000). - Optimizing specific nutrients before, during, and after the physiological processes of pregnancy and lactation can have a profound, positive, and comprehensive impact on the overall wellness of the developing and newborn child as well as the safety and health of the mother. Black, 85 B
RIT. J. NUTR. S193-97 (Supp. 2001); Scholl et al., 146 AMER. J. EPIDEM. 134-41 (1997). Nutrients provided to a mother reach the fetus. Specifically, it is established that substrates for growth and development, for example, circulate within the same pathways that carry drugs to and waste products from the fetus. Exchanges of material between mother and fetus occur primarily in the placenta, where villi containing fetal capillaries protrude into sinuses (intervillous spaces). Maternal arterial blood spurts into these spaces, then drains into maternal uterine veins to be returned to the maternal systemic circulation. Solutes in maternal blood cross the epithelial cells and connective tissue of the villi and the endothelium of the fetal capillaries; these solutes are then carried to the fetus by placental veins, which converge into the umbilical vein. THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 2022 (Mark H. Beers, M. D. & Robert Berkow, M. D. eds., 17th ed. 1999). - The compositions and methods of the present invention provide the means to optimize good health by utilizing vitamin and mineral nutritional supplementation. The compositions and methods of the present invention may be administered to or directed to a subject such as a human or any other organism.
- The compositions and methods of the present invention may comprise or use Vitamin A. This vitamin functions in physiological processes resulting in cellular differentiation, cellular maturity, and cellular specificity. Vitamin A is an important component of a nutritional supplement for subjects in a physiologically stressful state, such as pregnant or lactating women. Zile et al., 131(3) J. Nutr. 705-08 (2001). The compounds and methods of the present invention may comprise a form of Vitamin A, specifically, for example, the pro-vitamin A carotenoid beta carotene. Beta carotene is converted to Vitamin A within the body as needed. Mayne, 10 FASEB J. 690-701 (1996). The novel compositions and methods of the present invention may comprise or use Vitamin A, specifically in amounts ranging from about 2430 IU to about 2970 IU and, in a specific embodiment, around 2700 IU.
- The compositions and methods of the present invention may comprise or use Vitamin D. Vitamin D is a fat-soluble “hormone like” substance important for the maintenance of healthy bones. This vitamin increases the absorption of calcium and phosphorus from the gastrointestinal tract, and improves mineral resorption into bone tissue. Vitamin D can be converted to its active form from exposure of the skin to sunlight. This fact is among the reasons why Vitamin D deficiency is common in the elderly, notably the institutionalized, who spend little or no time out of doors. Deficiencies lead to increased bone turnover and loss, and when severe, osteomalacia, or softening of the bones. Supplementation with Vitamin D has been shown to moderately reduce bone loss, increase serum 25-hydroxyvitamin D, and decrease serum parathyroid hormone levels. Dawson-Hughes et al., 337 N
EW ENG. J. MED. 670-76 (1997); Lips et al., 86 J. CLIN. ENDOCRINOL. METAB. 1212-21 (2001). - The Vitamin D of the compositions and methods of the present invention may comprise Vitamin D3 (cholecalciferol). In the body, Vitamin D3 is produced when its precursor is exposed to ultraviolet irradiation (e.g., sunlight) and then hydroxylated in the liver to form 25-hydroxyvitamin D3, a form of Vitamin D in circulation. This form of the vitamin may be hydroxylated again in the kidney, yielding 1,25-hydroxyvitamin D3, a potent form of Vitamin D. Vitamin D3 plays a role in the maintenance of calcium and phosphorus homeostasis, but it is also active in cell differentiation and immune function. The novel compositions and methods of the present invention may comprise or use Vitamin D, specifically in amounts ranging from about 360 IU to about 440 IU and, in a specific embodiment, around 400 IU.
- The compositions and methods of the present invention may comprise or use Vitamin C (also known as ascorbic acid). The major biochemical role of the water-soluble Vitamin C is as a co-substrate in metal catalyzed hydroxylations. Vitamin C has antioxidant properties in interacting directly with superoxide hydroxyl radicals and singlet oxygen. Vitamin C also provides antioxidant protection for folate and Vitamin E, keeping Vitamin E in its most potent form.
- Lipid peroxidation has been associated with over 200 disease processes. Rock et al., 96(7) J. A
MER. DIET. ASSOC. 693-702 (1996). Specifically, lipid peroxidation may be implicated, for example, in the pathophysiology of preeclampsia, a toxemia of pregnancy. Vitamin C may afford protective effects against preeclampsia by participating in the scavenging of free radicals. Indeed, significantly lower levels of Vitamin C have been observed in preeclamptic women than in controls. Woods et al., 185(1) AM. J. OBSTET. GYNECOL. 5-10 (2001); Kharb, 1 EURO. J. OBSTET. GYNECOL. REPROD. BIOL. 37-39 (2000); Milczarek et al., 210 MOL. CELL. BIOCHEM. 65-73 (2000). - Vitamin C also enhances the absorption of iron. N
ATIONAL RESEARCH COUNCIL, RECOMMENDED DIETARY ALLOWANCES 115 (10th ed. 1989) (hereinafter “RDA”). In addition, Vitamin C is required for collagen synthesis, epinephrine synthesis, and bile acid formation. Moreover, Vitamin C has been implicated in inhibiting atherosclerosis by being present in extracellular fluid of the arterial wall and potentiating nitric oxide activity, thus normalizing vascular function. The novel compositions and methods of the present invention may comprise or use Vitamin C, specifically in amounts ranging from about 63 mg to about 77 mg and, in a specific embodiment, around 70 mg. - The compositions and methods of the present invention may comprise or use Vitamin E. Vitamin E is a fat-soluble vitamin antioxidant found in biological membranes where it protects the phospholipid membrane from oxidative stress. One form of Vitamin E, dl-alpha-tocopheryl acetate (BASF Corporation, Mount Olive, N.J.), is used to fortify foods and pharmaceuticals and may be used within the context of the present invention. Vitamin E inhibits the oxidation of unsaturated fatty acids by trapping peroxyl free radicals. It is also an antiatherogenic agent, and studies have demonstrated a reduced risk of coronary heart disease with increased intake of Vitamin E. Stampfer et al., 328 N
EW ENG. J. MED. 1444-49 (1993). In addition, Vitamin E, like Vitamin C, may afford protective effects against preeclampsia by participating in the scavenging of free radicals. Indeed, significantly lower levels of Vitamin E have been observed in preeclamptic women than in controls. Woods et al., 185(1) AM. J. OBSTET. GYNECOL. 5-10 (2001); Kharb, 1 EURO. J. OBSTET. GYNECOL. REPROD. BIOL. 37-39 (2000); Milczarek et al., 210 MOL. CELL. BIOCHEM. 65-73 (2000). The novel compositions and methods of the present invention may comprise or use Vitamin E, specifically in amounts ranging from about 27 IU to about 33 IU and, in a specific embodiment, around 30 IU. - The compositions and methods of the present invention may comprise or use B-complex vitamins. This class of vitamins comprises the water-soluble nutrients not generally stored in the body. The B-complex vitamins of the present compositions and methods may comprise one or more of thiamine (B1), riboflavin (B2), niacin (B3), folic acid, pyridoxine (B6) and cyanocobalamin (B12). B-complex vitamins play roles in a variety of biological processes critical to the health of pregnant women, lactating women, and fetuses such as, for example, the metabolism of homocysteine.
- The compositions and methods of the present invention may comprise or use folic acid. The B-complex vitamin folic acid has demonstrated the ability to prevent neural tube defects such as spina bifida caused by disturbed homocysteine metabolism. Vanderput et al., E
XP. BIOL. MED. 243-70 (2001); DeFalco et al., 27 CLIN. EXP. OBSTET. GYNECOL. 188-90 (2000); Eskes, 27 CLIN. EXP. OBSTET. GYNECOL. 157-67 (2000); Locksmith & Duff, 91 OBSTET. GYNECOL. 1027-34 (1998). Further, folic acid is important for the formation of red and white blood cells within bone marrow and plays a role in heme formation. RDA at 150. The novel compositions and methods of the present invention may comprise or use folic acid, specifically in amounts ranging from about 0.9 mg to about 1.1 mg and, in a specific embodiment, around 1.0 mg. - The compositions and methods of the present invention may comprise or use Vitamin B1. This vitamin plays a role in carbohydrate metabolism and neural function. It is a coenzyme for the oxidative decarboxylation of alpha-ketoacids (e.g., alpha-ketoglutarate and pyruvate) and for transketolase which is a component of the pentose phosphate pathway. Folate deficiency and malnutrition inhibit the activity of thiamine. RDA at 123. Vitamin B1 is available in forms known to those of skill in the art, including the form of thiamine mononitrate (BASF Corporation, Mount Olive, N.J.). The novel compositions and methods of the present invention may comprise or use Vitamin B1, specifically in amounts ranging from about 1.44 mg to about 1.76 mg and, in a specific embodiment, around 1.6 mg.
- The compositions and methods of the present invention may comprise or use Vitamin B2 (riboflavin). Riboflavin is a component of two flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These flavoenzymes are involved in a number of oxidation-reduction reactions including the conversion of pyridoxine and niacin. RDA at 132. Flavoenzymes also play a role in a number of metabolic pathways such as amino acid deamination, purine degradation, and fatty acid oxidation and thus help to maintain carbohydrate, amino acid, and lipid metabolism. The novel compositions and methods of the present invention may comprise or use Vitamin B2, specifically in amounts ranging from about 1.62 mg to about 1.98 mg and, in a specific embodiment, around 1.8 mg.
- The compositions and methods of the present invention may comprise or use Vitamin B6 (pyridoxine). The administration of pyridoxine may reduce the levels of homocysteine. Bostom et al., 49 K
IDNEY INT. 147-52 (1996). The active forms of pyridoxine, pyridoxal-5′-phosphate (PLP) and pyridoxamine-5′-phosphate, are coenzymes for numerous enzymes and as such, are important for gluconeogenesis, niacin formation, and erythrocyte metabolism. RDA at 142-43. Pyridoxine is a coenzyme for both cystathionine synthase and cystathionase, enzymes that catalyze the formation of cysteine from methionine. Homocysteine is an intermediate in this process and elevated levels of plasma homocysteine are recognized as a risk factor for both vascular disease (Robinson et al., 94 CIRCULATION 2743-48 (1996)) and neural tube defects (Locksmith & Duff, 91 OBSTET. GYNECOL. 1027-34 (1998)). Vitamin B6 is available in forms known to those of skill in the art, including the form of pyridoxine hydrochloride (BASF Corporation, Mount Olive, N.J.). The novel compositions and methods of the present invention may comprise or use Vitamin B6, specifically in amounts ranging from about 2.25 mg to about 2.75 mg and, in a specific embodiment, around 2.5 mg. - The compositions and methods of the present invention may comprise or use Vitamin B12. Cobalamin (a form of Vitamin B12) can be converted to the active coenzymes, methylcobalamin and 5′-deoxyadenosylcobalamin. These coenzymes are necessary for folic acid metabolism, conversion of coenzyme A, and myelin synthesis. For example, methylcobalamin catalyzes the demethylation of a folate cofactor which is involved in DNA synthesis. A lack of demethylation may result in folic acid deficiency. RDA at 159-60. Deoxyadenosylcobalamin is the coenzyme for the conversion of methylmalonyl-CoA to succinyl-CoA, which plays a role in the citric acid cycle. Importantly, cobalamin, along with pyridoxine and folic acid in implicated in the proper metabolism of homocysteine. Cobalamin is available as cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin, and hydroxycyanocobalamin. The novel compositions and methods of the present invention may comprise or use Vitamin B12, specifically in amounts ranging from about 10.8 mcg to about 13.2 mcg and, in a specific embodiment, around 12 mcg.
- The compositions and methods of the present invention may comprise or use niacin. Niacin, also called Vitamin B3, is the common name for two compounds: nicotinic acid (also called niacin) and niacinamide (also called nicotinamide). Niacin is particularly important for maintaining healthy levels and types of fatty acids. Niacin is also required for the synthesis of pyroxidine, riboflavin, and folic acid. RDA at 137. Administration of niacin may also effect a reduction in total cholesterol (LDL) and very low density lipoprotein (VLDL) levels and an increase in high density lipoprotein (HDL) cholesterol levels. Nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP) are active coenzymes of niacin. These coenzymes are involved in numerous enzymatic reactions such as glycolysis, fatty acid metabolism, and steroid synthesis. Henkin et al., 91 A
M. J. MED. 239-46 (1991). The novel compositions and methods of the present invention may comprise or use niacin, specifically in amounts ranging from about 16.2 mg to about 19.8 mg and, in a specific embodiment, around 18 mg. - Minerals are inorganic, or non-carbon-containing, elements that are critical for healthy physiological processes. Minerals are contemplated in the compositions and methods of the present invention. Such minerals may be in either chelated or non-chelated form. For example, minerals act as cofactors for hundreds of enzymes associated, for example, with food digestion, nucleic acid production, and protein synthesis. Minerals may also act as, for example, cofactors for antioxidant enzymes. The minerals of the compositions and methods of the present invention may comprise one or more of calcium, iron, magnesium, zinc, and copper.
- The compositions and methods of the present invention may comprise or use calcium in either chelated or non-chelated form. Chelation of calcium may affect its bioavailability. C
HELATED MINERALS, available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002). This mineral is required for proper functioning of numerous intracellular and extracellular processes including, for example, muscle contraction, nerve conduction, blood coagulation, and of particular interest in the context of pregnancy and lactation, hormone release. In addition, the calcium ion plays a unique role in intracellular signaling and is involved in the regulation of many enzymes. THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 139 (Mark H. Beers, M. D. & Robert Berkow, M. D. eds., 17th ed. 1999). Calcium is available in forms known to those of skill in the art, including the form of calcium carbonate, the active ingredient in TUMS® (GlaxoSmithKline, Research Triangle Park, N.C.). The novel compositions and methods of the present invention may comprise or use calcium, specifically in amounts ranging from about 90 mg to about 110 mg and, in a specific embodiment, around 100 mg. Further, the novel compositions and methods of the present invention may comprise or use calcium in amounts less than about 160 mg. In addition, the novel compositions and methods of the present invention may comprise or use calcium in amounts ranging from about 0.001 mg to about 160 mg. In addition, the novel compositions and methods of the present invention may comprise or use calcium in amounts of 0 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, 101 mg, 102 mg, 103 mg, 104 mg, 105 mg, 106 mg, 107 mg, 108 mg, 109 mg, 110 mg, 111 mg, 112 mg, 113 mg, 114 mg, 115 mg, 116 mg, 117 mg, 118 mg, 119 mg, 120 mg, 121 mg, 122 mg, 123 mg, 124 mg, 125 mg, 126 mg, 127 mg, 128 mg, 129 mg, 130 mg, 131 mg, 132 mg, 133 mg, 134 mg, 135 mg, 136 mg, 137 mg, 138 mg, 139 mg, 140 mg, 141 mg, 142 mg, 143 mg, 144 mg, 145 mg, 146 mg, 147 mg, 148 mg, 149 mg, 150 mg, 151 mg, 152 mg, 153 mg, 154 mg, 155 mg, 156 mg, 157 mg, 158 mg, 159 mg, or 160 mg. - The compositions and methods of the present invention may comprise or use iron in either chelated or non-chelated form. Chelation of iron may affect its bioavailability. C
HELATED MINERALS, available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002). A primary function of iron is to carry oxygen to bodily tissues via the hemoglobin part of red blood cells. Supplemental intake of iron is critical to preventing anemia, a disorder associated with a variety of physiological states including, for example, pregnancy. Bothwell, 72(Supp.) AM. J. CLIN. NUTR. 257S-64S (2000). Severe anemia may have adverse effects upon a mother and a fetus. Specifically, significant depression of hemoglobin has been associated with poor pregnancy outcome. Black, 85(Supp. 2) BRIT. J. NUTR. S193-97 (2001); Sifakis & Pharmakides, 900 ANN. N.Y. ACAD. SCI. 125-36 (2000). One form of iron known in the art is ferrous fumarate (Jost Chemical, St. Louis, Mo.). The novel compositions and methods of the present invention may comprise or use iron, specifically in amounts ranging from about 58.5 mg to about 71.5 mg and, in a specific embodiment, around 65 mg. In addition, the novel compositions and methods of the present invention may comprise or use iron in amounts more than about 20 mg. In addition, the novel compositions and methods of the present invention may comprise or use iron in amounts of 0 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, or 80 mg. - The compositions and methods of the present invention may comprise or use magnesium in either chelated or non-chelated form. Chelation of magnesium may affect its bioavailability. C
HELATED MINERALS, available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002). Magnesium is important for over 300 different enzyme reactions. A primary function of magnesium is to bind to phosphate groups in adenosine triphosphate (ATP), thereby forming a complex that assists in the transfer of ATP phosphate. Magnesium also functions within cells as an allosteric activator of enzyme activity and for membrane stabilization. Magnesium also plays roles in nucleic acid synthesis, transcription of DNA and RNA, amino acid activation, and protein synthesis. JAMES L. L. GROFF ET AL., ADVANCED NUTRITION AND HUMAN METABOLISM 341 (2d ed. 1996). - Magnesium is found primarily in both bone and muscle. Magnesium is related to the reactions of over 300 enzymes, including enzymes associated with biosynthetic pathways, glycolysis, protein synthesis, transketolase reactions, and membrane transport. Magnesium is also involved in the formation of cAMP, a cytosolic second messenger that plays a role in cell signaling mechanisms. In addition, magnesium functions both synergistically and antagonistically with calcium in neuromuscular transmission. RDA at 188. Specifically, magnesium is critical for the maintenance of electrochemical potentials of nerve and muscle membranes and the neuromuscular junction transmissions, particularly important in the heart. Not surprisingly, magnesium deficiency is tied to cardiovascular disease and hypertension. Agus et al., 17 C
RIT. CARE CLINICS 175-87 (2001). Indeed, oral magnesium therapy improves endothelial function in patients with coronary disease. Shechter et al., 102 CIRCULATION 2353-58 (2000). - Magnesium is available in a variety of salts. One form of magnesium known in the art is magnesium oxide (Mallinckrodt Baker, Inc., Phillipsburg, N.J.). The novel compositions and methods of the present invention may comprise or use magnesium, specifically in amounts ranging from about 22.5 mg to about 27.5 mg and, in a specific embodiment, around 25 mg.
- The compositions and methods of the present invention may comprise or use zinc in either chelated or non-chelated form. Chelation of zinc may affect its bioavailability. C
HELATED MINERALS, available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002). Zinc plays a role in numerous metabolic activities such as nucleic acid production, protein synthesis, and development of the immune system. There are more than 200 zinc metalloenzymes including aldolase, alcohol dehydrogenase, RNA polymerase, and protein kinase C. Zima et al., 17 BLOOD PURIF. 182-86 (1999). Zinc stabilizes RNA and DNA structures, forms zinc fingers in nuclear receptors, and is a component of chromatin proteins involved in transcription and replication. Deficiencies of zinc during pregnancy have been shown to contribute to severe fetal abnormalities. Srinivas et al., 68(6) INDIAN J. PEDIATR. 519-22 (2001); Yang et al., 13(4) BIOMED. ENVIRON. SCI. 280-86 (2000); King, 71(Supp.) AM. J. CLIN. NUTR. 1334S-43S (2000). Zinc is available in many forms, such as zinc oxide (Reade Advanced Materials, Providence, R.I.) and zinc sulfate (United States Biological, Swampscott, Mass.). The novel compositions and methods of the present invention may comprise or use zinc, specifically in amounts ranging from about 22.5 mg to about 27.5 mg and, in a specific embodiment, around 25 mg. - The compositions and methods of the present invention may comprise or use copper in either chelated or non-chelated form. Chelation of copper may affect its bioavailability. C
HELATED MINERALS, available at http://www.paws4us.com/minerals.html (last visited 08 Nov. 2002). Copper is an important component of the process of gene expression. Deficiencies of copper may lead to anemia, neutropenia, and bone abnormalities in pregnant and lactating women. In addition, a fetus must accumulate copper at a rate of 50 μg×kg−1×d−1 over the latter half of pregnancy; any deficiency in accumulation may lead to low birth weight and protein-energy malnutrition. Uauy et al., 67(Supp.) AMER. J. CLIN. NUTR. 952S-59S (1998). Many forms of copper are known to those skilled in the art, including copper oxide (Reade Advanced Materials, Providence, R.I.). The novel compositions and methods of the present invention may comprise or use copper, specifically in amounts ranging from about 1.8 mg to about 2.2 mg and, in a specific embodiment, around 2.0 mg. The novel compositions and methods of the present invention may comprise or use copper, specifically in amounts of 0 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2.0 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg, or 3.0 mg. - The compositions and methods of the present invention may comprise or use a combination of vitamins and minerals, in either chelated or non-chelated form, that work together with various metabolic systems and physiological responses of the human body. The active ingredients are available from numerous commercial sources, and in several active forms or salts thereof, known to those of ordinary skill in the art. Hence, the compositions and methods of the present invention are not limited to comprising or using any particular form of the vitamin or mineral ingredient described herein.
- The ingredients of the present invention may be combined into a composition which may be in the form of a solid powder, caplets, tablets, lozenges, pills, capsules, or a liquid, and which may be administered alone or in suitable combination with other components. For example, the composition of the present invention may be administered in one or more caplets or lozenges as practical for ease of administration. Each of the vitamins and minerals is commercially available, and can be blended to form a single composition or can form multiple compositions, which may be co-administered.
- To prepare the compositions of the present invention, each of the active ingredients may be combined in intimate admixture with a suitable carrier according to conventional compounding techniques. The carrier may take a wide variety of forms depending upon the form of the preparation desired for administration, e.g., oral, sublingual, nasal, via topical patch, or parenteral. The composition may consist of one to three caplets or lozenges, the composition of each preferably being identical to each other caplet or lozenge.
- In preparing the composition in oral dosage form, any usual media may be utilized. For liquid preparations (e.g., suspensions, elixirs, and solutions), media containing, for example water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used to prepare oral solids (e.g., powders, caplets, pills, tablets, capsules, and lozenges). Controlled release forms may also be used. Because of their ease in administration, caplets, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. All of these pharmaceutical carriers and formulations are well known to those of ordinary skill in the art. See generally, e.g., W
ADE & WALLER, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS (2nd ed. 1994). - Other objectives, features and advantages of the present invention will become apparent from the following specific examples. The specific examples, while indicating specific embodiments of the invention, are provided by way of illustration only. Accordingly, the present invention also includes those various changes and modifications within the spirit and scope of the invention that may become apparent to those skilled in the art from this detailed description. The invention will be further illustrated by the following non-limiting examples.
- Without further elaboration, it is believed that one skilled in the art, using the preceding description, can utilize the present invention to the fullest extent. The following examples are illustrative only, and not limiting of the remainder of the disclosure in any way whatsoever.
- A composition of the following formulation was prepared in caplet form, including the appropriate excipients, by standard methods known to those of ordinary skill in the art:
-
Vitamin A (beta carotene) 2700 IU Vitamin D (cholecalciferol) 400 IU Vitamin C (ascorbic acid) 70 mg Vitamin E (dl-alpha-tocopheryl acetate) 30 IU folic acid 1.0 mg Vitamin B1 (thiamine mononitrate) 1.6 mg Vitamin B2 (riboflavin) 1.8 mg Vitamin B6 (pyridoxine hydrochloride) 2.5 mg Vitamin B12 (cyanocobalamin) 12 mcg niacin (niacinamide) 18 mg calcium (calcium carbonate) 100 mg iron (ferrous fumarate) 65 mg magnesium (magnesium oxide) 25 mg zinc (zinc oxide) 25 mg copper (copper oxide) 2.0 mg - A study is undertaken to evaluate the effectiveness of the composition of the present invention in the treatment of patients. The objective of the study is to determine whether oral intake of the composition results in an improvement of the nutritional status of a patient in a physiologically stressful state.
- A double-blind, placebo controlled study is conducted over a six-month period. A total of 120 subjects (60 pregnant women entering the second trimester of pregnancy and 60 lactating women), aged 20-35 years, are chosen for the study. An initial assessment of the nutritional status of each woman is conducted utilizing methods such as the peroxide hemolysis test to assess Vitamin E deficiency, measurement of erythrocyte transketolase activity to determine thiamine levels, determination of erythrocyte glutathione reductase activity to assess riboflavin status, and high performance liquid chromatography to directly measure pyridoxine levels.
- The 120 subjects are separated into four separate groups of 30 women. In a first group comprising only pregnant women and in a second group comprising only lactating women, each subject is administered 2 caplets, daily, of the composition as described in Example 1. In a third group comprising only pregnant women and in a fourth group comprising only lactating women, each subject is administered 2 placebo caplets, daily. No other nutritional supplements are taken by the subjects during the assessment period.
- An assessment of the nutritional status of each woman is conducted utilizing methods such as the peroxide hemolysis test to assess Vitamin E deficiency, measurement of erythrocyte transketolase activity to determine thiamine levels, determination of erythrocyte glutathione reductase activity to assess riboflavin status, and high performance liquid chromatography to directly measure pyridoxine levels at one month intervals for a six month period. The data is evaluated using multiple linear regression analysis and a standard t-test. In each analysis, the baseline value of the outcome variable is included in the model as a covariant. Treatment by covariant interaction effects is tested by the method outlined by Weigel & Narvaez, 12 C
ONTROLLED CLINICAL TRIALS 378-94 (1991). If there are no significant interaction effects, the interaction terms are removed from the model. The regression model assumptions of normality and homogeneity of variance of residuals are evaluated by inspection of the plots of residuals versus predicted values. Detection of the temporal onset of effects is done sequentially by testing for the presence of significant treatment effects at 1, 2, 3, 4, 5, and 6 months, proceeding to the earlier time in sequence only when significant effects have been identified at each later time period. Changes from the baseline within each group are evaluated using paired t-tests. In addition, analysis of variance is performed on all baseline measurements and measurable subject characteristics to assess homogeneity between groups. All statistical procedures are conducted using the Statistical Analysis System (SAS Institute Inc., Cary, N.C.). An alpha level of 0.05 is used in all statistical tests. - A statistically significant improvement in the nutritional status with respect to Vitamin E, thiamine, riboflavin, and pyridoxine is observed in the treated subjects upon completion of the study over the controls. Therefore, the study confirms that oral administration of the composition of the present invention is effective in improving the nutritional status of a patient within a physiologically stressful state.
- While there has been described what is presently believed to be the preferred embodiments of the present invention, other and further modifications and changes may be made without departing from the spirit of the invention. All further and other modifications and changes are included that come within the scope of the invention as set forth in the claims. The disclosure of all publications cited above are expressly incorporated by reference in their entireties to the same extent as if each were incorporated by reference individually.
Claims (9)
1-250. (canceled)
251. A composition consisting of vitamin A, vitamin D, vitamin C, vitamin E, folic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, calcium, iron, and one or more pharmaceutical carriers.
252. The composition of claim 251 , wherein said composition consists of vitamin A, about 360 IU to about 440 IU vitamin D, vitamin C, about 27 IU to about 33 IU vitamin E, about 0.9 mg to about 1.1 mg folic acid, vitamin B1, about 1.62 mg to about 1.98 mg vitamin B2, about 2.25 mg to about 2.75 mg vitamin B6, vitamin B12, niacin, calcium, and about 58.5 mg to about 71.5 mg of iron.
253. The composition of claim 251 , wherein said composition consists of vitamin A, about 400 IU vitamin D, vitamin C, about 30 IU vitamin E, about 1.0 mg folic acid, vitamin B1, about 1.8 mg vitamin B2, about 2.5 mg vitamin B6, vitamin B12, niacin, calcium, and about 65 mg of iron.
254. A method consisting of administering to a patient the composition of claim 251 .
255. The method of claim 254 wherein said composition consists of vitamin A, about 360 IU to about 440 IU vitamin D, vitamin C, about 27 IU to about 33 IU vitamin E, about 0.9 mg to about 11 mg folic acid, vitamin B1, about 1.62 mg to about 1.98 mg vitamin B2, about 2.25 mg to about 2.75 mg vitamin B6, vitamin B12, niacin, calcium, and about 58.5 mg to about 71.5 mg of iron.
256. The method of claim 254 wherein said composition consists of vitamin A, about 400 IU vitamin D, vitamin C about 30 IU vitamin E, about 1.0 mg folic acid, vitamin B1, about 1.8 mg vitamin B2, about 2.5 mg vitamin B6, vitamin B12, niacin, calcium, and about 65 mg iron.
257. A composition consisting of vitamin A, vitamin D, vitamin C, vitamin E, folic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, calcium, non-chelated iron, magnesium, zinc, copper and one or more pharmaceutical carriers.
258. A method consisting of administering to a patient the composition of claim 257 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/143,464 US20080254142A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/315,159 US6814983B2 (en) | 2002-12-10 | 2002-12-10 | Compositions and methods for nutrition supplementation |
US10/790,027 US7390509B2 (en) | 2002-12-10 | 2004-03-02 | Compositions and methods for nutrition supplementation |
US12/143,464 US20080254142A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/790,027 Continuation US7390509B2 (en) | 2002-12-10 | 2004-03-02 | Compositions and methods for nutrition supplementation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080254142A1 true US20080254142A1 (en) | 2008-10-16 |
Family
ID=32468629
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/315,159 Expired - Lifetime US6814983B2 (en) | 2002-12-10 | 2002-12-10 | Compositions and methods for nutrition supplementation |
US10/790,027 Expired - Lifetime US7390509B2 (en) | 2002-12-10 | 2004-03-02 | Compositions and methods for nutrition supplementation |
US11/296,210 Abandoned US20060088603A1 (en) | 2002-12-10 | 2005-12-08 | Compositions and methods for nutrition supplementation |
US12/143,464 Abandoned US20080254142A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
US12/143,494 Abandoned US20080248133A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
US12/143,517 Abandoned US20080248132A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/315,159 Expired - Lifetime US6814983B2 (en) | 2002-12-10 | 2002-12-10 | Compositions and methods for nutrition supplementation |
US10/790,027 Expired - Lifetime US7390509B2 (en) | 2002-12-10 | 2004-03-02 | Compositions and methods for nutrition supplementation |
US11/296,210 Abandoned US20060088603A1 (en) | 2002-12-10 | 2005-12-08 | Compositions and methods for nutrition supplementation |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/143,494 Abandoned US20080248133A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
US12/143,517 Abandoned US20080248132A1 (en) | 2002-12-10 | 2008-06-20 | Compositions and methods for nutrition supplementation |
Country Status (4)
Country | Link |
---|---|
US (6) | US6814983B2 (en) |
EP (1) | EP1581200A4 (en) |
AU (1) | AU2003296357A1 (en) |
WO (1) | WO2004052295A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7449451B2 (en) * | 2001-08-29 | 2008-11-11 | Premier Micronutrient Corporation | Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks |
US6849613B2 (en) | 2001-08-29 | 2005-02-01 | Kedar N. Prasad | Multiple antioxidant micronutrients |
US7560123B2 (en) | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US8617617B2 (en) * | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
US6814983B2 (en) * | 2002-12-10 | 2004-11-09 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
US20060032448A1 (en) * | 2004-07-21 | 2006-02-16 | Kevin Schwartz | Shed no more |
US8101587B2 (en) | 2004-08-12 | 2012-01-24 | Everett Laboratories, Inc. | Kits for nutrition supplementation |
KR101361379B1 (en) * | 2005-04-13 | 2014-02-10 | 유키지루시 메그밀크 가부시키가이샤 | Nutrient composition |
US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US20110183951A1 (en) * | 2006-03-27 | 2011-07-28 | Salah Fathi Hussein | Copper (1) Complex |
WO2010009739A1 (en) * | 2008-07-22 | 2010-01-28 | Ibraheim Salah Fathiy Hussein | Copper(i)chloride complex of nicotinic acid and pharmaceutical compositions containing the same. |
US8287848B2 (en) * | 2006-10-03 | 2012-10-16 | Tris Pharma Inc | Formulations containing an ionic mineral-ion exchange resin complex and uses thereof |
US7565929B2 (en) | 2006-10-24 | 2009-07-28 | Schlumberger Technology Corporation | Degradable material assisted diversion |
CN101815509A (en) | 2007-08-03 | 2010-08-25 | 沙克利公司 | Nutritional dosage unit |
US9763989B2 (en) | 2007-08-03 | 2017-09-19 | Shaklee Corporation | Nutritional supplement system |
US9125844B1 (en) | 2007-09-25 | 2015-09-08 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US7964189B1 (en) | 2007-09-25 | 2011-06-21 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US8535660B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
US8535659B1 (en) | 2008-05-27 | 2013-09-17 | Argent Development Group, Llc | Nutritional supplements for pregnant women |
US20100047363A1 (en) * | 2008-11-07 | 2010-02-25 | John Wigneswaran | Nutritional supplement for patients with chronic kidney disease |
KR20120100964A (en) * | 2009-09-30 | 2012-09-12 | 바이타패스 제네틱스 인코포레이티드 | Cofactors and methods for use for individuals |
US20110135753A1 (en) * | 2009-12-04 | 2011-06-09 | John Wigneswaran | Nutritional Supplement For Patients With Chronic Heart Failure |
ES2362292B1 (en) * | 2009-12-11 | 2012-02-23 | Farmalider, S.A. | ORAL COMPOSITION SOLID PHARMACEUTICAL OR DIETARY SPECIFICALLY INDICATED FOR WOMEN MANAGER. |
US8840950B2 (en) | 2010-05-26 | 2014-09-23 | Jacqueline M. Hibbert | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
WO2012112551A2 (en) * | 2011-02-15 | 2012-08-23 | Cantilena Louis | Compositions and methods for nutrient supplementation of ethanol-containing beverages |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
JP2015518470A (en) | 2012-03-26 | 2015-07-02 | プロニュートリア・インコーポレイテッドPronutria, Inc. | Nutritional proteins and methods |
CA2868473A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Nutritive fragments, proteins and methods |
US9700071B2 (en) | 2012-03-26 | 2017-07-11 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
EP2831098A4 (en) | 2012-03-26 | 2016-12-07 | Axcella Health Inc | Charged nutritive proteins and methods |
EP3048904A2 (en) | 2013-09-25 | 2016-08-03 | Pronutria Biosciences, Inc. | Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof |
US10499682B2 (en) | 2014-08-25 | 2019-12-10 | New Age Beverage Corporation | Micronutrient formulation in electronic cigarettes |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
CN112056563A (en) * | 2020-09-15 | 2020-12-11 | 王胜林 | Nutrient composition for repairing lipid metabolism disorder and application thereof |
Citations (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3160564A (en) * | 1961-12-19 | 1964-12-08 | Merck & Co Inc | Multi-vitamin composition containing pantothenamide |
US3608083A (en) * | 1968-06-05 | 1971-09-21 | Hoffmann La Roche | Vitamin e powder |
US3846550A (en) * | 1971-01-21 | 1974-11-05 | H Akrongold | Cosmetic skin powder containing urea |
US4124710A (en) * | 1975-12-22 | 1978-11-07 | Labaz | Acetamidoxime derivatives and use thereof |
US4251550A (en) * | 1979-04-16 | 1981-02-17 | Elaine Powers Nutrition Company, Inc. | Meal replacement composition |
US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
US4431634A (en) * | 1981-12-21 | 1984-02-14 | American Cyanamid Company | Prenatal iron supplements |
US4547488A (en) * | 1984-04-16 | 1985-10-15 | Eli Lilly And Company | Antibiotic M43D, pharmaceutical compositions and method of use |
US4619829A (en) * | 1982-11-16 | 1986-10-28 | Georges Motschan | Utilization of a single vitamin or a combination of various vitamins |
US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
US4740373A (en) * | 1986-05-27 | 1988-04-26 | Usv Pharmaceutical Corporation | Stabilization of multivitamin/trace elements formulations |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
US4804535A (en) * | 1986-05-27 | 1989-02-14 | Rorer Pharmaceutical Corporation | Stabilization of multivitamin/trace elements formulations |
US4814102A (en) * | 1987-04-03 | 1989-03-21 | Basf Aktiengesellschaft | Detergents containing oxyalkylated, carboxyl-containing polymers |
US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
US4940658A (en) * | 1986-11-20 | 1990-07-10 | University Patents, Inc. | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency |
US4945083A (en) * | 1986-06-03 | 1990-07-31 | Jansen Jr Christian J | Safe oral folic-acid-containing vitamin preparation |
US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
US5215754A (en) * | 1986-12-30 | 1993-06-01 | American Cyanamid Company | Swallowable tablet containing polycarbophil |
US5215750A (en) * | 1991-09-04 | 1993-06-01 | Keane Ii Michael A | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control |
US5278329A (en) * | 1992-02-21 | 1994-01-11 | Zinpro Corporation | L-form 1:1 metal methionine complexes |
US5340594A (en) * | 1988-09-07 | 1994-08-23 | Omegatech Inc. | Food product having high concentrations of omega-3 highly unsaturated fatty acids |
US5340315A (en) * | 1991-06-27 | 1994-08-23 | Abbott Laboratories | Method of treating obesity |
US5374560A (en) * | 1989-04-03 | 1994-12-20 | The University Of Colorado, Inc. | Method for screening and distinguishing between cobalamin and folic acid deficiency based on assay for cystathionine and 2-methylcitric acid |
US5407957A (en) * | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
US5438017A (en) * | 1989-05-01 | 1995-08-01 | The University Of Colorado Foundation, Inc. | Assays for sulfhydryl amino acids and methylmalonic acid and their application to diagnosis of cobalamin deficiency |
US5457055A (en) * | 1986-11-20 | 1995-10-10 | The University Of Colorado Foundation | Diagnostic method for cobalamin deficiency |
US5494578A (en) * | 1987-01-30 | 1996-02-27 | Baxter International Inc. | Centrifugation pheresis system |
US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
US5556644A (en) * | 1992-11-05 | 1996-09-17 | Chandra Consultants | Nutritional supplement for the elderly |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5569458A (en) * | 1994-09-14 | 1996-10-29 | Greenberg; Mike | Nutritional formula |
US5626884A (en) * | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
US5686429A (en) * | 1995-01-13 | 1997-11-11 | Nestec Ltd | Method for providing nutrition to elderly patients |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US5869084A (en) * | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
US5898036A (en) * | 1997-07-28 | 1999-04-27 | Mcleod; Malcolm N. | Method of treating depression and pre-menstrual syndrome using chromium |
US5914129A (en) * | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
US5932624A (en) * | 1995-10-17 | 1999-08-03 | Herbert; Victor D. | Vitamin supplement composition |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US5965162A (en) * | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
US5997915A (en) * | 1996-01-31 | 1999-12-07 | South Alabama Medical Science Foundation | Compositions for human and animal consumption containing reduced folates and methods for making and using same |
US6039978A (en) * | 1995-06-06 | 2000-03-21 | Campbell Soup Company | Dietary food enhancement agent |
US6042849A (en) * | 1996-04-10 | 2000-03-28 | Chronorx, Llc | Unit dosage forms for treatment of vasoconstriction and related conditions |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6054128A (en) * | 1997-09-29 | 2000-04-25 | Wakat; Diane | Dietary supplements for the cardiovascular system |
US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
US6093425A (en) * | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US6102706A (en) * | 1995-06-06 | 2000-08-15 | Campbell Soup Company | Compliance support package for increasing health management system compliance |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6136859A (en) * | 1997-10-24 | 2000-10-24 | Pharma Nord Aps | Pharmaceutical formulation for treating liver disorders |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
US6207651B1 (en) * | 1996-08-02 | 2001-03-27 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US6214373B1 (en) * | 1999-10-07 | 2001-04-10 | Snowden-Sutton Associates, Inc. | Nutritional composition for treating inflammatory bowel diseases |
US6218192B1 (en) * | 1991-04-08 | 2001-04-17 | Research Foundation Of The State University Of New York | Method and composition for treatment of headache using magnesium |
US6228388B1 (en) * | 1992-09-23 | 2001-05-08 | Drugtech Corporation | Multi-vitamin and mineral supplement for pregnant women |
US6245360B1 (en) * | 1998-06-26 | 2001-06-12 | John S. Markowitz | Nutritional supplement |
US6255341B1 (en) * | 1998-02-25 | 2001-07-03 | Abbott Laboratories | Product and method reduce stress induced immune suppression |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6299896B1 (en) * | 2000-04-13 | 2001-10-09 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US20010028896A1 (en) * | 1998-05-28 | 2001-10-11 | Byrd Edward A. | Controlled release lipoic acid |
US20010036500A1 (en) * | 2000-02-28 | 2001-11-01 | Toshiaki Uchida | Folic acid and/or vitamin B12-lactoferrin complex |
US20020015742A1 (en) * | 1998-09-11 | 2002-02-07 | Jackson Sherry D. | Method of dietary supplementation |
US20020025310A1 (en) * | 2000-02-02 | 2002-02-28 | Bland Jeffrey S. | Compositions and methods for promoting healthy joints |
US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
US6440450B1 (en) * | 1998-07-25 | 2002-08-27 | Sam-Pharmaceutical Co., Ltd. | Soft chewable tablet comprising separated active ingredients |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US20020150607A1 (en) * | 2000-12-05 | 2002-10-17 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
US20020172721A1 (en) * | 1999-03-18 | 2002-11-21 | Atef Boulos | Vitamin formulation for cardiovascular health |
US6488956B1 (en) * | 1994-06-20 | 2002-12-03 | Drugtech Corporation | Multi-vitamin and mineral supplements for women |
US6495177B1 (en) * | 1999-08-13 | 2002-12-17 | Warner Chilcott Laboratories Ireland Limited | Orally dissolvable nutritional supplement |
US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
US20030049352A1 (en) * | 2001-05-31 | 2003-03-13 | Haile Mehansho | Fortified drinking water |
US20030050341A1 (en) * | 2001-09-12 | 2003-03-13 | Bydlon Roland J. | Vitamin/Mineral Compositions with DHA |
US20030148992A1 (en) * | 2000-03-27 | 2003-08-07 | Juergen Block | Sustained release vitamin composition |
US20030180393A1 (en) * | 2000-10-13 | 2003-09-25 | Stern Howard S. | Nutritional dietary system, formulation, kit and method for use in preparing an individual for a predetermined activity |
US20030206969A1 (en) * | 2002-05-02 | 2003-11-06 | Integrity Pharmaceutical Corporation | Prenatal multivitamin/multimineral supplement |
US20040043043A1 (en) * | 2000-09-20 | 2004-03-04 | Schlyter Jimmy Hirschsprung | Preparation of emulsions and concentrates thereof |
US6818228B1 (en) * | 1996-06-21 | 2004-11-16 | Mission Pharmacal Company | Dietary supplements containing ultradense calcium citrate and carbonyl iron |
US20060034916A1 (en) * | 2004-08-12 | 2006-02-16 | Giordano John A | Compositions and methods for nutrition supplementation |
US7390509B2 (en) * | 2002-12-10 | 2008-06-24 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB822127A (en) | 1957-11-25 | 1959-10-21 | Vitarine Company Inc | Stabilized multivitamin compositions containing vitamin b |
US6451567B1 (en) * | 1988-09-07 | 2002-09-17 | Omegatech, Inc. | Fermentation process for producing long chain omega-3 fatty acids with euryhaline microorganisms |
US4976568A (en) * | 1988-10-20 | 1990-12-11 | The Hopper Foundry (1977) Limited | Device for raising level of manhole cover |
US5308627A (en) * | 1990-08-07 | 1994-05-03 | Umbdenstock Jr Anthony J | Nutritional supplement for optimizing cellular health |
US5132113A (en) | 1990-10-26 | 1992-07-21 | Maurizio Luca | Nutritional composition containing essential amino acids |
US6410281B1 (en) * | 1992-07-10 | 2002-06-25 | Omegatech, Inc. | Reducing corrosion in a fermentor by providing sodium with a non-chloride sodium salt |
GB9407386D0 (en) * | 1994-04-14 | 1994-06-08 | Smithkline Beecham Plc | Pharmaceutical formulation |
EP0891719A1 (en) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
AU8898898A (en) | 1997-08-07 | 1999-03-01 | Ajay Gupta | Dialysis solutions containing water soluble vitamins and nutrients |
US6569857B1 (en) * | 1999-05-03 | 2003-05-27 | Drugtech Corporation | Dietary supplement |
US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
EP2341126A3 (en) * | 2000-01-28 | 2011-10-05 | Martek Biosciences Corporation | Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors |
US20010028897A1 (en) * | 2000-02-18 | 2001-10-11 | Milton Hammerly | Compositions and treatment methods for benign prostatic hypertrophy |
US20020044969A1 (en) * | 2000-05-22 | 2002-04-18 | Jerome Harden | Method for increasing the compressibility of poorly binding powder materials |
US6579544B1 (en) * | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
JP2003012554A (en) | 2001-06-26 | 2003-01-15 | Takashi Azumaguchi | Composition for alleviating invasion and wound treatment promotion |
JP2003059028A (en) | 2001-08-20 | 2003-02-28 | Fuji Photo Film Co Ltd | Magnetic recording medium |
US6849613B2 (en) * | 2001-08-29 | 2005-02-01 | Kedar N. Prasad | Multiple antioxidant micronutrients |
-
2002
- 2002-12-10 US US10/315,159 patent/US6814983B2/en not_active Expired - Lifetime
-
2003
- 2003-12-09 EP EP03812872A patent/EP1581200A4/en not_active Withdrawn
- 2003-12-09 WO PCT/US2003/039022 patent/WO2004052295A2/en not_active Application Discontinuation
- 2003-12-09 AU AU2003296357A patent/AU2003296357A1/en not_active Abandoned
-
2004
- 2004-03-02 US US10/790,027 patent/US7390509B2/en not_active Expired - Lifetime
-
2005
- 2005-12-08 US US11/296,210 patent/US20060088603A1/en not_active Abandoned
-
2008
- 2008-06-20 US US12/143,464 patent/US20080254142A1/en not_active Abandoned
- 2008-06-20 US US12/143,494 patent/US20080248133A1/en not_active Abandoned
- 2008-06-20 US US12/143,517 patent/US20080248132A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3160564A (en) * | 1961-12-19 | 1964-12-08 | Merck & Co Inc | Multi-vitamin composition containing pantothenamide |
US3608083A (en) * | 1968-06-05 | 1971-09-21 | Hoffmann La Roche | Vitamin e powder |
US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
US3846550A (en) * | 1971-01-21 | 1974-11-05 | H Akrongold | Cosmetic skin powder containing urea |
US4124710A (en) * | 1975-12-22 | 1978-11-07 | Labaz | Acetamidoxime derivatives and use thereof |
US4251550A (en) * | 1979-04-16 | 1981-02-17 | Elaine Powers Nutrition Company, Inc. | Meal replacement composition |
US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
US4431634A (en) * | 1981-12-21 | 1984-02-14 | American Cyanamid Company | Prenatal iron supplements |
US4619829A (en) * | 1982-11-16 | 1986-10-28 | Georges Motschan | Utilization of a single vitamin or a combination of various vitamins |
US4547488A (en) * | 1984-04-16 | 1985-10-15 | Eli Lilly And Company | Antibiotic M43D, pharmaceutical compositions and method of use |
US4710387A (en) * | 1984-11-09 | 1987-12-01 | Melkunte Holland B.V. | Nutritional supplement preparation intended for pregnant and breast-feeding women based on milk constituents as well as a process for preparing it |
US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
US4740373A (en) * | 1986-05-27 | 1988-04-26 | Usv Pharmaceutical Corporation | Stabilization of multivitamin/trace elements formulations |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
US4804535A (en) * | 1986-05-27 | 1989-02-14 | Rorer Pharmaceutical Corporation | Stabilization of multivitamin/trace elements formulations |
US4945083A (en) * | 1986-06-03 | 1990-07-31 | Jansen Jr Christian J | Safe oral folic-acid-containing vitamin preparation |
US4940658A (en) * | 1986-11-20 | 1990-07-10 | University Patents, Inc. | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5457055A (en) * | 1986-11-20 | 1995-10-10 | The University Of Colorado Foundation | Diagnostic method for cobalamin deficiency |
US5215754A (en) * | 1986-12-30 | 1993-06-01 | American Cyanamid Company | Swallowable tablet containing polycarbophil |
US5494578A (en) * | 1987-01-30 | 1996-02-27 | Baxter International Inc. | Centrifugation pheresis system |
US4814102A (en) * | 1987-04-03 | 1989-03-21 | Basf Aktiengesellschaft | Detergents containing oxyalkylated, carboxyl-containing polymers |
US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
US5340594A (en) * | 1988-09-07 | 1994-08-23 | Omegatech Inc. | Food product having high concentrations of omega-3 highly unsaturated fatty acids |
US5374560A (en) * | 1989-04-03 | 1994-12-20 | The University Of Colorado, Inc. | Method for screening and distinguishing between cobalamin and folic acid deficiency based on assay for cystathionine and 2-methylcitric acid |
US5438017A (en) * | 1989-05-01 | 1995-08-01 | The University Of Colorado Foundation, Inc. | Assays for sulfhydryl amino acids and methylmalonic acid and their application to diagnosis of cobalamin deficiency |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5407957A (en) * | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
US5492938A (en) * | 1990-02-13 | 1996-02-20 | Martek Biosciences Corporation | Pharmaceutical composition and dietary supplement containing docosarexaenoic acid obtained from dinoflagellates |
US6218192B1 (en) * | 1991-04-08 | 2001-04-17 | Research Foundation Of The State University Of New York | Method and composition for treatment of headache using magnesium |
US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
US5340315A (en) * | 1991-06-27 | 1994-08-23 | Abbott Laboratories | Method of treating obesity |
US5215750A (en) * | 1991-09-04 | 1993-06-01 | Keane Ii Michael A | L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control |
US5278329A (en) * | 1992-02-21 | 1994-01-11 | Zinpro Corporation | L-form 1:1 metal methionine complexes |
US6228388B1 (en) * | 1992-09-23 | 2001-05-08 | Drugtech Corporation | Multi-vitamin and mineral supplement for pregnant women |
US5556644A (en) * | 1992-11-05 | 1996-09-17 | Chandra Consultants | Nutritional supplement for the elderly |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US6297224B1 (en) * | 1992-12-29 | 2001-10-02 | Metabolite Laboratories, Inc. | Method for treatment, preventing and reduction of elevated serum metabolite levels |
US6528496B1 (en) * | 1992-12-29 | 2003-03-04 | Allen Robert H | Compositions treating, preventing or reducing elevated metabolic levels |
US5965162A (en) * | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US20030068372A1 (en) * | 1994-06-20 | 2003-04-10 | Drugtech Corporation | Nutritional composition |
US5869084A (en) * | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
US20020187205A1 (en) * | 1994-06-20 | 2002-12-12 | K-V Pharmaceutical Company | Multi-vitamin and mineral supplements for women |
US6488956B1 (en) * | 1994-06-20 | 2002-12-03 | Drugtech Corporation | Multi-vitamin and mineral supplements for women |
US5569458A (en) * | 1994-09-14 | 1996-10-29 | Greenberg; Mike | Nutritional formula |
US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
US5686429A (en) * | 1995-01-13 | 1997-11-11 | Nestec Ltd | Method for providing nutrition to elderly patients |
USRE36288E (en) * | 1995-01-13 | 1999-08-31 | Nestec Ltd. | Method for providing nutrition to elderly patients |
US6039978A (en) * | 1995-06-06 | 2000-03-21 | Campbell Soup Company | Dietary food enhancement agent |
US6102706A (en) * | 1995-06-06 | 2000-08-15 | Campbell Soup Company | Compliance support package for increasing health management system compliance |
US5626884A (en) * | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
US5932624A (en) * | 1995-10-17 | 1999-08-03 | Herbert; Victor D. | Vitamin supplement composition |
US5997915A (en) * | 1996-01-31 | 1999-12-07 | South Alabama Medical Science Foundation | Compositions for human and animal consumption containing reduced folates and methods for making and using same |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US6042849A (en) * | 1996-04-10 | 2000-03-28 | Chronorx, Llc | Unit dosage forms for treatment of vasoconstriction and related conditions |
US6818228B1 (en) * | 1996-06-21 | 2004-11-16 | Mission Pharmacal Company | Dietary supplements containing ultradense calcium citrate and carbonyl iron |
US5914129A (en) * | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
US6207651B1 (en) * | 1996-08-02 | 2001-03-27 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
US5898036A (en) * | 1997-07-28 | 1999-04-27 | Mcleod; Malcolm N. | Method of treating depression and pre-menstrual syndrome using chromium |
US6054128A (en) * | 1997-09-29 | 2000-04-25 | Wakat; Diane | Dietary supplements for the cardiovascular system |
US6136859A (en) * | 1997-10-24 | 2000-10-24 | Pharma Nord Aps | Pharmaceutical formulation for treating liver disorders |
US6093425A (en) * | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US5922704A (en) * | 1997-12-24 | 1999-07-13 | Feeling Fine Company Llc | Optimal nutritional supplement for men |
US6255341B1 (en) * | 1998-02-25 | 2001-07-03 | Abbott Laboratories | Product and method reduce stress induced immune suppression |
US6048846A (en) * | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US20010028896A1 (en) * | 1998-05-28 | 2001-10-11 | Byrd Edward A. | Controlled release lipoic acid |
US6245360B1 (en) * | 1998-06-26 | 2001-06-12 | John S. Markowitz | Nutritional supplement |
US6440450B1 (en) * | 1998-07-25 | 2002-08-27 | Sam-Pharmaceutical Co., Ltd. | Soft chewable tablet comprising separated active ingredients |
US6444218B2 (en) * | 1998-07-25 | 2002-09-03 | Sam-A-Pharmaceuticals Co. Ltd. | Soft chewable multivitamin tablet comprising separated active ingredients |
US20020015742A1 (en) * | 1998-09-11 | 2002-02-07 | Jackson Sherry D. | Method of dietary supplementation |
US20020172721A1 (en) * | 1999-03-18 | 2002-11-21 | Atef Boulos | Vitamin formulation for cardiovascular health |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
US6495177B1 (en) * | 1999-08-13 | 2002-12-17 | Warner Chilcott Laboratories Ireland Limited | Orally dissolvable nutritional supplement |
US6214373B1 (en) * | 1999-10-07 | 2001-04-10 | Snowden-Sutton Associates, Inc. | Nutritional composition for treating inflammatory bowel diseases |
US20020034543A1 (en) * | 1999-12-01 | 2002-03-21 | Drugtech Corporation | Nutritional composition |
US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
US20020025310A1 (en) * | 2000-02-02 | 2002-02-28 | Bland Jeffrey S. | Compositions and methods for promoting healthy joints |
US20010036500A1 (en) * | 2000-02-28 | 2001-11-01 | Toshiaki Uchida | Folic acid and/or vitamin B12-lactoferrin complex |
US20030148992A1 (en) * | 2000-03-27 | 2003-08-07 | Juergen Block | Sustained release vitamin composition |
US6299896B1 (en) * | 2000-04-13 | 2001-10-09 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US20040043043A1 (en) * | 2000-09-20 | 2004-03-04 | Schlyter Jimmy Hirschsprung | Preparation of emulsions and concentrates thereof |
US20030180393A1 (en) * | 2000-10-13 | 2003-09-25 | Stern Howard S. | Nutritional dietary system, formulation, kit and method for use in preparing an individual for a predetermined activity |
US20020192265A1 (en) * | 2000-12-05 | 2002-12-19 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity-maintaining agents |
US6569445B2 (en) * | 2000-12-05 | 2003-05-27 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity maintaining-agents |
US20030108594A1 (en) * | 2000-12-05 | 2003-06-12 | Pbm Pharmaceuticals Inc. | Food bars containing nutritional supplements |
US20020150607A1 (en) * | 2000-12-05 | 2002-10-17 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
US20030049352A1 (en) * | 2001-05-31 | 2003-03-13 | Haile Mehansho | Fortified drinking water |
US20030050341A1 (en) * | 2001-09-12 | 2003-03-13 | Bydlon Roland J. | Vitamin/Mineral Compositions with DHA |
US20030206969A1 (en) * | 2002-05-02 | 2003-11-06 | Integrity Pharmaceutical Corporation | Prenatal multivitamin/multimineral supplement |
US7390509B2 (en) * | 2002-12-10 | 2008-06-24 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US20060034916A1 (en) * | 2004-08-12 | 2006-02-16 | Giordano John A | Compositions and methods for nutrition supplementation |
Also Published As
Publication number | Publication date |
---|---|
US20040109901A1 (en) | 2004-06-10 |
US20080248133A1 (en) | 2008-10-09 |
WO2004052295A2 (en) | 2004-06-24 |
AU2003296357A8 (en) | 2004-06-30 |
AU2003296357A1 (en) | 2004-06-30 |
EP1581200A2 (en) | 2005-10-05 |
US6814983B2 (en) | 2004-11-09 |
WO2004052295A3 (en) | 2004-09-16 |
US20060088603A1 (en) | 2006-04-27 |
US7390509B2 (en) | 2008-06-24 |
EP1581200A4 (en) | 2008-10-29 |
US20040166175A1 (en) | 2004-08-26 |
US20080248132A1 (en) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7390509B2 (en) | Compositions and methods for nutrition supplementation | |
US6863904B2 (en) | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects | |
US10201560B2 (en) | Compositions and methods for nutrition supplementation | |
US8617617B2 (en) | Methods and kits for co-administration of nutritional supplements | |
US8101587B2 (en) | Kits for nutrition supplementation | |
US20100196508A1 (en) | Method and composition for supplementation of nutritional deficiencies in renal patients | |
US6995166B1 (en) | Method and composition for supplementation of nutritional deficiencies in renal patients | |
US20070036869A1 (en) | Methods for prophylactic and therapeutic nutritional supplementation | |
Aleksandrova et al. | Biochemistry of vitamins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |